|
YTD 2017
|
Q3 2017
|
||||
$m
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER1
|
Actual
|
CER
|
||
Total
Revenue
|
16,688
|
(4)
|
(3)
|
6,232
|
9
|
10
|
Product Sales
|
14,665
|
(9)
|
(8)
|
4,882
|
(3)
|
(2)
|
Externalisation Revenue
|
2,023
|
49
|
50
|
1,350
|
n/m
|
n/m
|
|
|
|
|
|
|
|
Reported
Operating Profit
|
2,991
|
26
|
16
|
1,149
|
12
|
9
|
Core
Operating Profit2
|
5,068
|
8
|
5
|
1,853
|
9
|
9
|
|
|
|
|
|
|
|
Reported
Earnings Per Share (EPS)
|
$1.34
|
3
|
(4)
|
$0.54
|
(32)
|
(33)
|
Core
EPS
|
$2.98
|
(4)
|
(7)
|
$1.12
|
(15)
|
(17)
|
Regulatory
Approvals
|
Faslodex - breast cancer (1st
line) (US)
Lynparza - ovarian cancer (2nd
line, 4th line/tablets) (US)
Calquence (acalabrutinib) -
blood cancer (mantle cell lymphoma (MCL), 2nd line)
(US)
Brilinta - prior myocardial
infarction (MI) (CN)
Farxiga + Bydureon - type-2 diabetes (US, EU)
Bydureon BCise (autoinjector) - type-2 diabetes
(US)
Symbicort - chronic obstructive
pulmonary disease (COPD) exacerbations (US)
|
Regulatory
Submission Acceptances
|
Lynparza - breast cancer (US,
JP) (Priority Reviews)
Imfinzi - locally-advanced,
unresectable lung cancer (US/Priority Review, EU,
JP)
Bydureon BCise - type-2 diabetes (EU)
|
Major
Phase
III
Data
Readouts
|
moxetumomab
pasudotox - leukaemia (met
primary endpoint)
Duaklir - COPD (met primary endpoint)
tralokinumab
- severe, uncontrolled asthma (did not meet primary
endpoints)
|
Other
Major Developments
|
Tagrisso - lung cancer (1st line): Breakthrough Therapy
Designation (US)
Imfinzi - locally-advanced, unresectable lung cancer: Breakthrough
Therapy Designation (US)
|
|
Updated Guidance
|
Prior Guidance
|
Total Revenue
|
A low
to mid single-digit percentage decline
|
A low
to mid single-digit percentage decline
|
Core EPS
|
Towards
the favourable end of a low to mid teens percentage
decline*
|
A low
to mid teens percentage decline
|
Q4
2017
|
Tagrisso - lung cancer (1st
line): Regulatory submission
benralizumab - severe, uncontrolled asthma: Regulatory decision
(US)
|
H1
2018
|
Lynparza - ovarian cancer (2nd line): Regulatory decision
(EU, JP)
Lynparza - ovarian cancer (1st line): Data
readout
Lynparza - breast cancer: Regulatory decision (US),
regulatory submission (EU)
Imfinzi - lung cancer (PACIFIC): Regulatory decision
(US)
Imfinzi +/- treme - lung cancer (ARCTIC): Data readout,
regulatory submission
Imfinzi +/- treme - lung cancer (MYSTIC): Data readout
(final overall survival)
Imfinzi +/- treme - head
& neck cancer (KESTREL): Data
readout
Imfinzi +/- treme - head & neck cancer (EAGLE): Data
readout
moxetumomab
pasudotox - leukaemia:
Regulatory submission
selumetinib
- thyroid cancer: Data readout, regulatory submission
Bevespi - COPD: Regulatory
submission (JP)
Duaklir - COPD: Regulatory submission (US)
benralizumab
- severe, uncontrolled asthma: Regulatory decision (EU,
JP)
PT010 -
COPD: Data readout
|
H2
2018
|
Lynparza - breast cancer: Regulatory decision
(JP)
Lynparza - ovarian cancer (1st line): Regulatory
submission
Imfinzi - lung cancer (PACIFIC): Regulatory decision (EU,
JP)
Imfinzi +/- treme - lung cancer
(MYSTIC): Regulatory submission
Imfinzi + treme - lung cancer (NEPTUNE): Data readout,
regulatory submission
Imfinzi +/- treme - head
& neck cancer (KESTREL):
Regulatory submission
Imfinzi +/- treme - head & neck cancer (EAGLE):
Regulatory submission
Farxiga - type-2 diabetes
(DECLARE): Data readout
Bydureon BCise - type-2 diabetes: Regulatory decision
(EU)
roxadustat
- anaemia: Regulatory
submission (US)
Bevespi - COPD: Regulatory
decision (EU)
benralizumab - COPD: Data readout, regulatory
submission
PT010 -
COPD: Regulatory submission (JP)
anifrolumab
- lupus: Data
readout
|
Media Relations
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203
749 5638
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
Karen
Birmingham
|
UK/Global
|
+44 203
749 5634
|
Matt
Kent
|
UK/Global
|
+44 203
749 5906
|
Gonzalo
Viña
|
UK/Global
|
+44 203
749 5916
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
|
|
Investor Relations
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
Craig
Marks
|
Finance;
Fixed Income; M&A
|
+44
7881 615 764
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
Mitchell
Chan
|
Oncology;
Other
|
+1 240
477 3771
|
Christer
Gruvris
|
Brilinta; Diabetes
|
+44 203
749 5716
|
Nick
Stone
|
Respiratory;
Renal
|
+44 203
749 5711
|
US toll
free
|
|
+1 866
381 7277
|
|
YTD 2017
|
Q3 2017
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Total
Revenue
|
16,688
|
(4)
|
(3)
|
6,232
|
9
|
10
|
|
|
|
|
|
|
|
Product Sales
|
14,665
|
(9)
|
(8)
|
4,882
|
(3)
|
(2)
|
Externalisation Revenue
|
2,023
|
49
|
50
|
1,350
|
n/m
|
n/m
|
|
YTD 2017
|
Q3 2017
|
||||
$m
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
||
Emerging Markets
|
4,519
|
5
|
7
|
1,515
|
9
|
10
|
Respiratory
|
3,372
|
(5)
|
(3)
|
1,092
|
(2)
|
(2)
|
New
CVMD
|
2,543
|
5
|
5
|
873
|
7
|
7
|
Japan
|
1,645
|
3
|
5
|
578
|
(3)
|
4
|
New
Oncology
|
876
|
96
|
97
|
339
|
72
|
73
|
|
|
|
|
|
|
|
Total*
|
11,055
|
3
|
4
|
3,760
|
5
|
6
|
Medicine
|
Partner
|
Region
|
$m
|
Lynparza &
selumetinib
|
MSD
-
initial revenue
|
Global
|
997
|
Zoladex
|
TerSera
Therapeutics LLC (TerSera)- initial revenue
|
US and
Canada
|
250
|
anaesthetics
|
Aspen
Global, Inc. (Aspen)
-
milestone revenue
|
Global
(excl.US)
|
150
|
Siliq
|
Valeant
Pharmaceuticals International, Inc. (Valeant)
-
milestone revenue
|
US
|
130
|
MEDI8897
|
Sanofi
Pasteur, Inc. (Sanofi Pasteur)
-
initial revenue
|
Global
|
127
|
Tudorza/Duaklir
|
Circassia
Pharmaceuticals plc (Circassia)
-
initial revenue
|
US
|
64
|
lanabecestat
|
Eli
Lilly and Company (Lilly)
-
milestone revenue
|
Global
|
50
|
MEDI1341
|
Takeda
Pharmaceutical Company Limited (Takeda)
-
initial revenue
|
Global
|
50
|
Other
|
|
|
205
|
|
|
|
|
Total
|
|
|
2,023
|
|
YTD 2017
|
Q3 2017
|
||||||
|
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
||
Actual
|
CER
|
Actual
|
CER
|
|||||
Royalties
|
100
|
5
|
22
|
25
|
31
|
2
|
14
|
57
|
|
|
|
|
|
|
|
|
|
Milestones/Other
|
431
|
21
|
104
|
109
|
272
|
20
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
Total Sustainable and Ongoing Externalisation Revenue
|
531
|
26
|
81
|
85
|
303
|
22
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
Initial Revenue
|
1,492
|
74
|
40
|
39
|
1,047
|
78
|
63
|
60
|
|
|
|
|
|
|
|
|
|
Total Externalisation Revenue
|
2,023
|
100
|
49
|
49
|
1,350
|
100
|
n/m
|
n/m
|
Medicine
|
Region
|
Completion
|
Product Sales in
Impacted Regions
|
||
YTD 2016
|
YTD 2017*
|
Difference
|
|||
$m
|
$m
|
$m
|
|||
Toprol-XL
|
US
|
October 2016
|
81
|
34
|
(47)
|
Bydureon/Byetta
|
China
|
October 2016
|
9
|
-
|
(9)
|
antibiotics
|
Global
(excl. US)
|
December 2016
|
143
|
28
|
(115)
|
Zoladex
|
US and
Canada
|
March 2017
|
50
|
24
|
(26)
|
Seloken
|
Europe
|
June 2017
|
67
|
48
|
(19)
|
Zomig
|
Global
(excl. Japan)
|
June 2017
|
56
|
45
|
(11)
|
|
|
|
|
|
|
Total
|
|
|
406
|
179
|
(227)
|
Proportion of YTD 2017 Product Sales
|
|
|
|
|
-2%
|
Announcement
|
Medicine
|
Partner
|
Region
|
Externalisation Revenue
|
July 2017
|
Lynparza
|
MSD
|
Global
|
●
Initial $1.0bn revenue
●
Up to $0.75bn for certain licence
options
●
Up to $6.15bn in regulatory and sales
milestones
|
March 2017
|
MEDI8897
|
Sanofi
Pasteur
|
Global
|
●
Initial €120m revenue
●
Up to €495m in sales and
development-related milestones
|
February 2017
|
Zoladex
|
TerSera
|
US and
Canada
|
●
Initial $250m revenue
●
Up to $70m in sales-related
milestones
●
Mid-teen percentage royalties on
sales
|
October 2016
|
Toprol-XL
|
Aralez
Pharmaceuticals Inc.
|
US
|
●
Initial $175m revenue
●
Up to $48m milestone and sales-related
revenue
●
Mid-teen percentage royalties on
sales
|
July 2016
|
tralokinumab - atopic dermatitis
|
LEO
Pharma A/S
(LEO
Pharma)
|
Global
|
●
Initial $115m revenue
●
Up to $1bn in commercially-related
milestones
●
Up to mid-teen tiered percentage royalties on
sales
|
September 2015
|
Siliq
|
Valeant
|
Global,
later
amended
to US
|
●
Initial $100m revenue
●
Pre-launch milestone of $130m
●
Sales-related royalties up to
$175m
●
Profit sharing
|
March 2015
|
Movantik
|
Daiichi
Sankyo Company, Ltd
(Daiichi
Sankyo)
|
US
|
●
Initial $200m revenue
●
Up to $625m in sales-related
revenue
|
Therapy Area
|
Medicine
|
YTD 2017
|
Q3 2017
|
||||||
$m
|
% of total*
|
% change
|
$m
|
% of total
|
% change
|
||||
Actual
|
CER
|
Actual
|
CER
|
||||||
Oncology
|
Tagrisso
|
651
|
4
|
136
|
138
|
248
|
5
|
86
|
89
|
Iressa
|
398
|
3
|
1
|
2
|
137
|
3
|
10
|
10
|
|
Lynparza
|
197
|
1
|
26
|
26
|
81
|
2
|
40
|
36
|
|
Imfinzi
|
1
|
-
|
n/m
|
n/m
|
-
|
-
|
-
|
-
|
|
Legacy:
|
|
|
|
|
|
|
|
|
|
Faslodex
|
703
|
5
|
16
|
16
|
241
|
5
|
16
|
16
|
|
Zoladex
|
548
|
4
|
(6)
|
(5)
|
185
|
4
|
(7)
|
(6)
|
|
Casodex
|
161
|
1
|
(14)
|
(12)
|
51
|
1
|
(18)
|
(16)
|
|
Arimidex
|
160
|
1
|
(9)
|
(6)
|
54
|
1
|
(4)
|
(2)
|
|
Others
|
85
|
1
|
13
|
16
|
29
|
1
|
7
|
15
|
|
Total Oncology
|
2,904
|
20
|
18
|
19
|
1,026
|
21
|
18
|
19
|
|
CVMD
|
Brilinta
|
780
|
5
|
29
|
31
|
284
|
6
|
37
|
36
|
Farxiga
|
742
|
5
|
24
|
24
|
285
|
6
|
30
|
29
|
|
Onglyza
|
431
|
3
|
(25)
|
(25)
|
127
|
3
|
(25)
|
(25)
|
|
Bydureon
|
427
|
3
|
(2)
|
(2)
|
128
|
3
|
(12)
|
(12)
|
|
Byetta
|
128
|
1
|
(36)
|
(35)
|
39
|
1
|
(36)
|
(36)
|
|
Symlin
|
35
|
-
|
30
|
30
|
10
|
-
|
(9)
|
(9)
|
|
Legacy:
|
|
|
|
|
|
|
|
|
|
Crestor
|
1,771
|
12
|
(36)
|
(35)
|
580
|
12
|
(16)
|
(14)
|
|
Seloken/Toprol-XL
|
527
|
4
|
(6)
|
(4)
|
160
|
3
|
(14)
|
(12)
|
|
Atacand
|
227
|
2
|
(3)
|
(1)
|
80
|
2
|
10
|
11
|
|
Others
|
259
|
2
|
(16)
|
(14)
|
80
|
2
|
(6)
|
(5)
|
|
Total CVMD
|
5,327
|
36
|
(16)
|
(14)
|
1,773
|
36
|
(4)
|
(4)
|
|
Respiratory
|
Symbicort
|
2,051
|
14
|
(9)
|
(8)
|
668
|
14
|
(4)
|
(4)
|
Pulmicort
|
805
|
5
|
4
|
7
|
242
|
5
|
8
|
9
|
|
Daliresp/Daxas
|
145
|
1
|
28
|
28
|
53
|
1
|
26
|
26
|
|
Tudorza/Eklira
|
108
|
1
|
(19)
|
(18)
|
37
|
1
|
(21)
|
(21)
|
|
Duaklir
|
56
|
-
|
27
|
30
|
21
|
-
|
50
|
43
|
|
Bevespi
|
8
|
-
|
n/m
|
n/m
|
4
|
-
|
n/m
|
n/m
|
|
Others
|
199
|
1
|
(13)
|
(12)
|
67
|
1
|
(22)
|
(22)
|
|
Total Respiratory
|
3,372
|
23
|
(5)
|
(3)
|
1,092
|
22
|
(2)
|
(2)
|
|
Other
|
Nexium
|
1,525
|
10
|
(1)
|
-
|
469
|
10
|
(9)
|
(7)
|
Synagis
|
453
|
3
|
21
|
21
|
153
|
3
|
47
|
47
|
|
Losec/Prilosec
|
202
|
1
|
(7)
|
(5)
|
66
|
1
|
(8)
|
(8)
|
|
Seroquel XR
|
224
|
2
|
(64)
|
(64)
|
62
|
1
|
(67)
|
(68)
|
|
Movantik/Moventig
|
92
|
1
|
42
|
42
|
30
|
1
|
20
|
20
|
|
FluMist/Fluenz
|
20
|
-
|
(46)
|
(46)
|
20
|
-
|
(23)
|
(23)
|
|
Others
|
546
|
4
|
(40)
|
(39)
|
191
|
4
|
(30)
|
(29)
|
|
Total Other
|
3,062
|
21
|
(19)
|
(18)
|
991
|
20
|
(18)
|
(17)
|
|
|
Total
Product Sales
|
14,665
|
100
|
(9)
|
(8)
|
4,882
|
100
|
(3)
|
(2)
|
|
YTD 2017
|
Q3 2017
|
||||||||
$m
|
% of total1
|
% change
|
$m
|
% of total
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
|||||||
Emerging
Markets2
|
4,519
|
31
|
5
|
7
|
1,515
|
31
|
9
|
10
|
||
|
China
|
2,142
|
15
|
6
|
10
|
723
|
15
|
12
|
14
|
|
|
Ex. China
|
2,377
|
16
|
4
|
5
|
792
|
16
|
5
|
7
|
|
|
|
|
|
|
|
|
|
|
||
US
|
4,399
|
30
|
(23)
|
(23)
|
1,386
|
28
|
(10)
|
(10)
|
||
|
|
|
|
|
|
|
|
|
||
Europe
|
3,460
|
24
|
(7)
|
(6)
|
1,188
|
24
|
(6)
|
(8)
|
||
|
|
|
|
|
|
|
|
|
||
Established
ROW
|
2,287
|
16
|
1
|
1
|
793
|
16
|
(4)
|
-
|
||
|
Japan
|
1,645
|
11
|
3
|
5
|
578
|
12
|
(3)
|
4
|
|
|
Canada
|
353
|
2
|
(5)
|
(6)
|
115
|
2
|
(9)
|
(10)
|
|
|
Other
Established ROW
|
289
|
2
|
(6)
|
(9)
|
100
|
2
|
(6)
|
(10)
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
||
Total
|
14,665
|
100
|
(9)
|
(8)
|
4,882
|
100
|
(3)
|
(2)
|
|
Reported
|
|||
YTD 2017
|
YTD 2016
|
Actual
|
CER
|
|
$m
|
$m
|
% change
|
|
|
Total
Revenue
|
16,688
|
17,417
|
(4)
|
(3)
|
Product Sales
|
14,665
|
16,059
|
(9)
|
(8)
|
Externalisation Revenue
|
2,023
|
1,358
|
49
|
50
|
|
|
|
|
|
Cost of
Sales
|
(3,093)
|
(2,966)
|
4
|
9
|
\
|
|
|
|
|
Gross
Profit
|
13,595
|
14,451
|
(6)
|
(5)
|
Gross Margin*
|
80.3%
|
81.7%
|
-1
|
-2
|
|
|
|
|
|
Distribution
Expense
|
(225)
|
(243)
|
(8)
|
(4)
|
% Total Revenue
|
1.3%
|
1.4%
|
-
|
-
|
R&D
Expense
|
(4,206)
|
(4,347)
|
(3)
|
(1)
|
% Total Revenue
|
25.2%
|
25.0%
|
-
|
-1
|
SG&A
Expense
|
(7,155)
|
(8,027)
|
(11)
|
(9)
|
% Total Revenue
|
42.9%
|
46.1%
|
+3
|
+3
|
Other
Operating Income and Expense
|
982
|
535
|
83
|
86
|
% Total Revenue
|
5.9%
|
3.1%
|
+3
|
+3
|
|
|
|
|
|
Operating
Profit
|
2,991
|
2,369
|
26
|
16
|
% Total Revenue
|
17.9%
|
13.6%
|
+4
|
+3
|
Net
Finance Expense
|
(1,128)
|
(978)
|
15
|
4
|
Joint
Ventures and Associates
|
(43)
|
(22)
|
89
|
89
|
Profit
Before Tax
|
1,820
|
1,369
|
33
|
24
|
Taxation
|
(213)
|
220
|
|
|
Tax
Rate
|
12%
|
(16)%
|
|
|
Profit
After Tax
|
1,607
|
1,589
|
1
|
(6)
|
|
|
|
|
|
Earnings Per
Share
|
$1.34
|
$1.31
|
3
|
(4)
|
|
Reported
|
|||
Q3 2017
|
Q3 2016
|
Actual
|
CER
|
|
$m
|
$m
|
% change
|
||
Total
Revenue
|
6,232
|
5,699
|
9
|
10
|
Product Sales
|
4,882
|
5,025
|
(3)
|
(2)
|
Externalisation Revenue
|
1,350
|
674
|
n/m
|
n/m
|
|
|
|
|
|
Cost of
Sales
|
(1,249)
|
(900)
|
39
|
40
|
\
|
|
|
|
|
Gross
Profit
|
4,983
|
4,799
|
4
|
4
|
Gross Margin*
|
77.7%
|
82.2%
|
-4
|
-4
|
|
|
|
|
|
Distribution
Expense
|
(76)
|
(76)
|
(1)
|
1
|
% Total Revenue
|
1.2%
|
1.3%
|
-
|
-
|
R&D
Expense
|
(1,404)
|
(1,402)
|
-
|
1
|
% Total Revenue
|
22.5%
|
24.6%
|
+2
|
+2
|
SG&A
Expense
|
(2,497)
|
(2,403)
|
4
|
5
|
% Total Revenue
|
40.1%
|
42.2%
|
+2
|
+2
|
Other
Operating Income and Expense
|
143
|
110
|
29
|
29
|
% Total Revenue
|
2.3%
|
1.9%
|
-
|
-
|
|
|
|
|
|
Operating
Profit
|
1,149
|
1,028
|
12
|
9
|
% Total Revenue
|
18.4%
|
18.0%
|
-
|
-
|
Net
Finance Expense
|
(386)
|
(342)
|
13
|
5
|
Joint
Ventures and Associates
|
(17)
|
(10)
|
60
|
60
|
Profit
Before Tax
|
746
|
676
|
10
|
11
|
Taxation
|
(97)
|
319
|
|
|
Tax
Rate
|
13%
|
(47)%
|
|
|
Profit
After Tax
|
649
|
995
|
(35)
|
(36)
|
|
|
|
|
|
Earnings Per
Share
|
$0.54
|
$0.80
|
(32)
|
(33)
|
|
YTD
2017
|
Q3
2017
|
||||
|
$m
|
%
change
|
$m
|
%
change
|
||
|
|
Actual
|
CER
|
|
Actual
|
CER
|
Reported Profit
Before Tax
|
1,820
|
33
|
24
|
746
|
10
|
11
|
Net Finance
Expense
|
1,128
|
15
|
4
|
386
|
13
|
5
|
Joint Ventures and
Associates
|
43
|
89
|
89
|
17
|
60
|
60
|
Depreciation,
Amortisation and Impairment
|
1,929
|
9
|
12
|
655
|
7
|
7
|
EBITDA*
|
4,920
|
19
|
15
|
1,804
|
10
|
9
|
YTD
2017
|
Reported
|
Restructuring
|
Intangible Asset
Amortisation & Impairments
|
Diabetes Alliance
|
Other1
|
Core2
|
Core
|
|
Actual
|
CER
|
|||||||
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
% change
|
||
Gross
Profit
|
13,595
|
128
|
103
|
-
|
-
|
13,826
|
(6)
|
(5)
|
Gross Margin3
|
80.3%
|
-
|
-
|
-
|
-
|
81.8%
|
-1
|
-1
|
|
|
|
|
|
|
|
|
|
Distribution
Expense
|
(225)
|
-
|
-
|
-
|
-
|
(225)
|
(8)
|
(4)
|
R&D
Expense
|
(4,206)
|
177
|
73
|
-
|
-
|
(3,956)
|
(5)
|
(2)
|
SG&A
Expense
|
(7,155)
|
265
|
773
|
235
|
204
|
(5,678)
|
(7)
|
(5)
|
Other
Operating Income and Expense
|
982
|
75
|
44
|
-
|
-
|
1,101
|
91
|
94
|
|
|
|
|
|
|
|
|
|
Operating
Profit
|
2,991
|
645
|
993
|
235
|
204
|
5,068
|
8
|
5
|
% Total Revenue
|
17.9%
|
-
|
-
|
-
|
-
|
30.4%
|
+3
|
+2
|
|
|
|
|
|
|
|
|
|
Net
Finance Expense
|
(1,128)
|
-
|
-
|
234
|
368
|
(526)
|
8
|
5
|
|
|
|
|
|
|
|
|
|
Taxation
|
(213)
|
(135)
|
(240)
|
(144)
|
(86)
|
(818)
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share
|
$1.34
|
$0.40
|
$0.59
|
$0.26
|
$0.39
|
$2.98
|
(4)
|
(7)
|
Q3
2017
|
Reported
|
Restructuring
|
Intangible Asset
Amortisation & Impairments
|
Diabetes Alliance
|
Other1
|
Core2
|
Core
|
|
Actual
|
CER
|
|||||||
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
% change
|
||
Gross
Profit
|
4,983
|
47
|
45
|
-
|
-
|
5,075
|
4
|
4
|
Gross Margin3
|
77.7%
|
-
|
-
|
-
|
-
|
79.6%
|
-4
|
-4
|
|
|
|
|
|
|
|
|
|
Distribution
Expense
|
(76)
|
-
|
-
|
-
|
-
|
(76)
|
(1)
|
1
|
R&D
Expense
|
(1,404)
|
35
|
30
|
-
|
-
|
(1,339)
|
-
|
-
|
SG&A
Expense
|
(2,497)
|
68
|
265
|
102
|
112
|
(1,950)
|
3
|
4
|
Other
Operating Income and Expense
|
143
|
(1)
|
1
|
-
|
-
|
143
|
32
|
32
|
|
|
|
|
|
|
|
|
|
Operating
Profit
|
1,149
|
149
|
341
|
102
|
112
|
1,853
|
9
|
9
|
% Total Revenue
|
18.4%
|
-
|
-
|
-
|
-
|
29.7%
|
-
|
-
|
|
|
|
|
|
|
|
|
|
Net
Finance Expense
|
(386)
|
-
|
-
|
70
|
147
|
(169)
|
(2)
|
3
|
|
|
|
|
|
|
|
|
|
Taxation
|
(97)
|
(31)
|
(78)
|
(37)
|
(46)
|
(289)
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share
|
$0.54
|
$0.09
|
$0.21
|
$0.11
|
$0.17
|
$1.12
|
(15)
|
(17)
|
|
YTD 2017
|
YTD 2016
|
Difference
|
$m
|
$m
|
$m
|
|
Reported operating
profit
|
2,991
|
2,369
|
622
|
Depreciation,
amortisation and impairment
|
1,929
|
1,767
|
162
|
|
|
|
|
(Increase)/decrease
in working capital and short-term provisions
|
(228)
|
(472)
|
244
|
(Gains)/losses on
disposal of intangible assets
|
(735)
|
(198)
|
(537)
|
Fair
value movement on contingent consideration arising from business
combinations
|
(62)
|
132
|
(194)
|
Non-cash and other
movements
|
(322)
|
(479)
|
157
|
Interest
paid
|
(519)
|
(489)
|
(30)
|
Tax
paid
|
(473)
|
(445)
|
(28)
|
|
|
|
|
Net
cash inflow from operating activities
|
2,581
|
2,185
|
396
|
|
At 30 Sep 2017
|
At 31 Dec 2016
|
At 30 Sep 2016
|
$m
|
$m
|
$m
|
|
Cash
and cash equivalents
|
4,036
|
5,018
|
3,090
|
Other
investments
|
1,255
|
898
|
927
|
Net
derivatives
|
427
|
235
|
267
|
|
|
|
|
Cash,
short-term investments and derivatives
|
5,718
|
6,151
|
4,284
|
|
|
|
|
Overdrafts and
short-term borrowings
|
(930)
|
(451)
|
(1,075)
|
Finance
leases
|
(12)
|
(93)
|
(97)
|
Current
instalments of loans
|
-
|
(1,769)
|
(1,775)
|
Loans
due after one year
|
(16,910)
|
(14,495)
|
(14,736)
|
|
|
|
|
Interest-bearing
loans and borrowings (gross debt)
|
(17,852)
|
(16,808)
|
(17,683)
|
|
|
|
|
Net
Debt
|
(12,134)
|
(10,657)
|
(13,399)
|
|
Average Exchange Rates Versus USD
|
|
Impact Of 5% Strengthening in Exchange Rate Versus USD
($m)1
|
|||
Currency
|
Primary Relevance
|
FY 2016
|
YTD 20172
|
% change
|
Total Revenue
|
Core Operating Profit
|
EUR
|
Product Sales
|
0.90
|
0.90
|
+1
|
+179
|
+123
|
JPY
|
Product Sales
|
108.84
|
111.93
|
-3
|
+104
|
+71
|
CNY
|
Product Sales
|
6.65
|
6.80
|
-2
|
+131
|
+74
|
SEK
|
Costs
|
8.56
|
8.62
|
-1
|
+7
|
-98
|
GBP
|
Costs
|
0.74
|
0.78
|
-6
|
+29
|
-131
|
Other3
|
|
|
|
|
+194
|
+124
|
Regulatory
Approvals
|
9
|
-
Faslodex - breast cancer
(1st line) (US)
-
Lynparza - ovarian cancer
(2nd line, 4th line/tablets) (US)
-
Calquence (acalabrutinib) -
MCL (2nd line) (US)
-
Brilinta - prior MI
(CN)
-
Farxiga + Bydureon - type-2 diabetes (US,
EU)
-
Bydureon BCise - type-2 diabetes
(US)
-
Symbicort - COPD
exacerbations (US)
|
Regulatory
Submission
Acceptances
|
6
|
-
Lynparza - breast cancer
(US, JP) (Priority Reviews)
-
Imfinzi - locally-advanced,
unresectable NSCLC ((US/Priority Review), EU, JP)
-
Bydureon BCise - type-2 diabetes
(EU)
|
Major
Phase III
Data Readouts
|
5
|
- Tagrisso - lung cancer (1st line) (FLAURA) (met primary
endpoint)
- Imfinzi - lung cancer (MYSTIC) (did not meet PFS primary
endpoint)
-
moxetumomab pasudotox - leukaemia (met primary
endpoint)
- Duaklir - COPD (met primary endpoint)
-
tralokinumab - severe, uncontrolled
asthma (did not meet primary endpoints)
|
Other Major Developments
|
3
|
-
Tagrisso - lung cancer (1st
line)
(Breakthrough
Therapy Designation, US)
-
Imfinzi - locally-advanced,
unresectable lung cancer
(Breakthrough
Therapy Designation, US)
-
Calquence - MCL (2nd
line)
(Breakthrough
Therapy Designation, US)
|
New Molecular Entities(NMEs) in Phase III Trials or Under
Regulatory Review
|
11
|
Oncology
- Imfinzi + treme - multiple cancers
-
moxetumomab pasudotox - leukaemia
-
selumetinib - thyroid cancer
-
savolitinib - kidney cancer
CVMD
- ZS-9 (sodium zirconium
cyclosilicate) - hyperkalaemia*
-
roxadustat - anaemia*
Respiratory
-
benralizumab - severe, uncontrolled asthma*, COPD
-
tralokinumab - severe, uncontrolled asthma
-
PT010 - COPD
Other
-
anifrolumab - lupus
-
lanabecestat - Alzheimer's disease
|
Projects in Clinical Pipeline
|
129
|
|
Name
|
Phase
|
Line of Treatment
|
Population
|
Design
|
Timelines
|
Status
|
Monotherapy
|
||||||
ADJUVANT*
|
III
|
N/A
|
Stage Ib-IIIa NSCLC
|
Imfinzi vs
placebo
|
FPCD1
Q1 2015
First data anticipated 2020
|
Recruitment ongoing
|
PACIFIC
|
III
|
N/A
|
Locally-advanced (Stage III), unresectable NSCLC
|
Imfinzi vs
placebo
|
FPCD Q2 2014
LPCD2
Q2 2016
Final OS data anticipated 2019
|
Recruitment completed
PFS primary endpoint met
|
PEARL
|
III
|
1st line
|
NSCLC (Asia)
|
Imfinzi vs SoC
chemotherapy
|
FPCD Q1 2017
First data anticipated 2020
|
Recruitment ongoing
|
Combination therapy
|
||||||
MYSTIC
|
III
|
1st line
|
NSCLC
|
Imfinzi, Imfinzi + treme vs SoC chemotherapy
|
FPCD Q3 2015
LPCD Q3 2016
Final OS data anticipated H1 2018
|
Recruitment completed
PFS primary endpoint not met
|
NEPTUNE
|
III
|
1st line
|
NSCLC
|
Imfinzi + treme vs SoC
chemotherapy
|
FPCD Q4 2015
LPCD Q2 2017
First data anticipated H2 2018
|
Recruitment completed
|
POSEIDON
|
III
|
1st line
|
NSCLC
|
Imfinzi + SoC,
Imfinzi
+ treme + SoC vs SoC
chemotherapy
|
FPCD Q2 2017
First data anticipated 2019
|
Recruitment ongoing
|
ARCTIC
|
III
|
3rd line
|
PDL1- low/neg. NSCLC
|
Imfinzi, tremelimumab,
Imfinzi
+ treme vs SoC
chemotherapy
|
FPCD Q2 2015
LPCD Q3 2016
First data anticipated H1 2018
|
Recruitment completed
|
CASPIAN
|
III
|
1st line
|
Small-cell lung cancer (SCLC)
|
Imfinzi + SoC,
Imfinzi
+ treme + SoC vs SoC
chemotherapy
|
FPCD Q1 2017
First data anticipated 2020
|
Recruitment ongoing
|
Name
|
Phase
|
Line of Treatment
|
Population
|
Design
|
Timelines
|
Status
|
DANUBE
|
III
|
1st line
|
Cisplatin chemotherapy- eligible/
ineligible bladder cancer
|
Imfinzi, Imfinzi + treme vs SoC chemotherapy
|
FPCD Q4 2015
LPCD Q1 2017
First data anticipated 2019
|
Recruitment completed
|
KESTREL
|
III
|
1st line
|
Head and neck squamous cell carcinoma (HNSCC, head and neck
cancer)
|
Imfinzi, Imfinzi + treme vs SoC
|
FPCD Q4 2015
LPCD Q1 2017
First data anticipated H1 2018
|
Recruitment completed
|
EAGLE
|
III
|
2nd line
|
HNSCC
|
Imfinzi, Imfinzi + treme vs SoC
|
FPCD Q4 2015
LPCD Q3 2017
First data anticipated H1 2018
|
Recruitment completed
|
HIMALAYA
|
III
|
1st line
|
HCC
|
Imfinzi, Imfinzi + treme vs sorafenib
|
First data anticipated 2019
|
Recruitment ongoing
|
Medicine
|
Trial
|
Mechanism
|
Population
|
Primary Endpoint
|
Timeline
|
Farxiga
|
DECLARE
|
SGLT2 inhibitor
|
~17,0001
patients with type-2
diabetes
|
Time to first occurrence of CV death, non-fatal MI or non-fatal
stroke
|
H2 2018 (final analysis)
|
Farxiga
|
DAPA-HF
|
SGLT2 inhibitor
|
~4,500 patients with heart failure (HF)
|
Time to first occurrence of CV death or hospitalisation for HF or
an urgent HF visit
|
FPCD Q1 2017
|
Farxiga
|
DAPA-CKD
|
SGLT2 inhibitor
|
~4,000 patients with chronic kidney disease (CKD)
|
Time to first occurrence of ≥50% sustained decline in
eGFR2
or reaching ESRD3
or CV death or renal
death
|
FPCD Q1 2017
|
Brilinta
|
THEMIS
|
P2Y12 receptor antagonist
|
~19,000 patients with type-2 diabetes
and coronary artery disease
without a history of
MI or stroke
|
Composite of
CV death, non-fatal MI
and non-fatal stroke
|
2019
|
Epanova
|
STRENGTH
|
Omega-3 carboxylic acids
|
~13,000 patients with mixed dyslipidaemia
|
Time to first occurrence of CV death, non-fatal MI or non-fatal
stroke
|
2019
|
|
|
|
|
Estimated
Regulatory Acceptance Date /Submission Status
|
||||
Compound
|
Mechanism
|
Area
Under Investigation
|
Date
Commenced Phase
|
US
|
EU
|
Japan
|
China
|
|
Oncology
|
|
|
|
|
|
|
|
|
Calquence# (acalabrutinib)
|
BTK
inhibitor
|
B-cell
malignancy
|
Q1
2015
|
Approved
|
|
|
|
|
Calquence# (acalabrutinib)
|
BTK
inhibitor
|
1st-line
chronic lymphocytic leukaemia
|
Q3
2015
|
2020
(Orphan
Drug Designation)
|
2020
(Orphan
designation)
|
|
|
|
Calquence# (acalabrutinib)
|
BTK
inhibitor
|
relapsed/refractory
chronic lymphocytic leukaemia, high risk
|
Q4
2015
|
2020
(Orphan
Drug Designation)
|
2020
(Orphan
designation)
|
|
|
|
Calquence# (acalabrutinib)
|
BTK
inhibitor
|
1st-line mantle cell lymphoma
|
Q1
2017
|
2023
|
|
|
|
|
savolitinib#
SAVOIR
|
MET inhibitor
|
papillary renal cell carcinoma
|
Q3
2017
|
2020
|
2020
|
|
|
|
selumetinibASTRA
|
MEK
inhibitor
|
differentiated
thyroid cancer
|
Q3
2013
|
H2
2018
(Orphan
Drug Designation)
|
H2
2018
|
|
|
|
moxetumomab
pasudotox#
PLAIT
|
anti-CD22
recombinantimmunotoxin
|
hairy
cell leukaemia
|
Q2
2013
|
H1
2018
(Orphan
Drug Designation)
|
|
|
|
|
Imfinzi#
+
tremelimumabARCTIC
|
PD-L1
mAb + CTLA-4 mAb
|
3rd-line
NSCLC
|
Q2
2015
|
H1
2018
|
H1
2018
|
H1
2018
|
|
|
Imfinzi#
+ tremelimumab
MYSTIC
|
PD-L1
mAb + CTLA-4 mAb
|
1st-line
NSCLC
|
Q3
2015
|
H2
2018
|
H2
2018
|
H2
2018
|
|
|
Imfinzi#
+ tremelimumab
NEPTUNE
|
PD-L1
mAb + CTLA-4 mAb
|
1st-line
NSCLC
|
Q4
2015
|
2019
|
2019
|
2019
|
2020
|
|
Imfinzi#PACIFIC
|
PD-L1
mAb
|
locally-advanced
(Stage III), NSCLC
|
Q2
2014
|
Accepted
(Breakthrough
Therapy Designation & Priority Review)
|
Accepted
|
Accepted
|
|
|
Imfinzi#
+ tremelimumab + chemotherapy
POSEIDON
|
PD-L1
mAb + CTLA-4 mAb
|
1st-line
NSCLC
|
Q2
2017
|
2019
|
2019
|
2019
|
2020
|
|
Imfinzi#
+ tremelimumab + SoC
CASPIAN
|
PD-L1
mAb + CTLA-4 mAb + SoC
|
1st-line
small cell lung cancer
|
Q1
2017
|
2020
|
2020
|
2020
|
|
|
Imfinzi#
+ tremelimumabKESTREL
|
PD-L1
mAb + CTLA-4 mAb
|
1st-line
HNSCC
|
Q4
2015
|
H2
2018
|
H2
2018
|
H2
2018
|
|
|
Imfinzi# +
tremelimumabEAGLE
|
PD-L1
mAb + CTLA-4 mAb
|
2nd-line
HNSCC
|
Q4
2015
|
H2
2018
|
H2
2018
|
H2
2018
|
|
|
Imfinzi#
+ tremelimumab
DANUBE
|
PD-L1
mAb + CTLA-4 mAb
|
1st-line
bladder cancer
|
Q4
2015
|
2019
|
2019
|
2019
|
|
|
Lynparza#¶+ cediranib
CONCERTO
|
PARP
inhibitor + VEGF inhibitor
|
recurrent
platinum-resistant ovarian cancer
|
Q1
2017
|
2019
|
|
|
|
|
CVMD
|
|
|
|
|
|
|||
Epanova
|
omega-3 carboxylic acids
|
severe hypertriglycerid-aemia
|
|
Approved
|
|
2020
|
|
|
ZS-9 (sodium zirconium cyclosilicate)
|
potassium binder
|
hyperkalaemia
|
|
-
|
Accepted1
|
2019
|
|
|
roxadustat#
OLYMPUS (US) ROCKIES
(US)
|
hypoxia-inducible factor prolyl hydroxylase inhibitor
|
anaemia in CKD / end-stage renal disease
|
Q3
2014
|
H2
2018
|
|
|
Accepted2
|
|
Respiratory
|
||||||||
Bevespi Aerosphere (PT003)
|
LABA/LAMA
|
COPD
|
|
Launched
|
Accepted
|
H2
2018
|
H2
2018
|
|
benralizumab#
CALIMA SIROCCO ZONDA
BISE
BORA
GREGALE
|
IL-5R mAb
|
severe, uncontrolled asthma
|
|
Accepted
|
Accepted
|
Accepted
|
2021
|
|
benralizumab#
TERRANOVA GALATHEA
|
IL-5R mAb
|
COPD
|
Q3
2014
|
H2
2018
|
H2
2018
|
2019
|
|
|
PT010
|
LABA/LAMA/
ICS
|
COPD
|
Q3
2015
|
2019
|
2019
|
H2
2018
|
H2
2018
|
|
tralokinumab
STRATOS 1,2
TROPOS
MESOS
|
IL-13 mAb
|
severe, uncontrolled asthma
|
Q3
2014
|
-
|
-
|
-
|
|
|
Other
|
|
|
|
|
|
|
|
|
anifrolumab#
TULIP
|
IFN-alphaR mAb
|
systemic lupus erythematosus
|
Q3
2015
|
2019
(Fast
Track)
|
2019
|
2019
|
|
|
lanabecestat#
AMARANTH + extension, DAYBREAK-ALZ
|
beta-secretase inhibitor
|
Alzheimer's disease
|
Q2
2016
|
2020
(Fast
Track)
|
2020
|
2020
|
|
Compound
|
Mechanism
|
Area Under Investigation
|
Phase
|
Date Commenced Phase
|
Oncology
|
|
|
|
|
Imfinzi#
|
PD-L1 mAb
|
solid tumours
|
II
|
Q3
2014
|
Imfinzi#
+ tremelimumab
|
PD-L1
mAb + CTLA-4 mAb
|
HCC
|
II
|
Q4
2016
|
Imfinzi#
+ tremelimumab
|
PD-L1
mAb + CTLA-4 mAb
|
gastric
cancer
|
II
|
Q2
2015
|
Imfinzi#
+ AZD5069
|
PD-L1 mAb + CXCR2 antagonist
|
pancreatic ductal adenocarcinoma
|
II
|
Q2
2017
|
Imfinzi#
+ AZD5069 or Imfinzi# +
AZD9150#
|
PD-L1 mAb + CXCR2 antagonist or PD-L1 mAb + STAT3
inhibitor
|
HNSCC
|
II
|
Q3
2015
|
Imfinzi#
+ dabrafenib +
trametinib
|
PD-L1 mAb + BRAF inhibitor + MEK inhibitor
|
melanoma
|
I
|
Q1
2014
|
Imfinzi# +
AZD1775#
|
PD-L1 mAb + Wee1 inhibitor
|
solid tumours
|
I
|
Q4 2015
|
Imfinzi#
+ MEDI0680
|
PD-L1 mAb + PD-1 mAb
|
solid tumours
|
II
|
Q3
2016
|
Imfinzi#
or Imfinzi#
+ (tremelimumab or
AZD9150#)
|
PD-L1 mAb or PD-L1 mAb + (CTLA-4 mAb or STAT3
inhibitor)
|
diffuse large B-cell lymphoma
|
I
|
Q3
2016
|
Imfinzi#
+
Iressa
|
PD-L1 mAb + EGFR inhibitor
|
NSCLC
|
I
|
Q2
2014
|
Imfinzi#
+ MEDI0562#
|
PD-L1 mAb + humanised OX40 agonist
|
solid tumours
|
I
|
Q2 2016
|
Imfinzi# +
MEDI9197#
|
PD-L1 mAb + TLR 7/8 agonist
|
solid tumours
|
I
|
Q2
2017
|
Imfinzi#
+ MEDI9447
|
PD-L1 mAb + CD73 mAb
|
solid tumours
|
I
|
Q1
2016
|
Imfinzi#
+ monalizumab
|
PD-L1 mAb + NKG2a mAb
|
solid tumours
|
I
|
Q1
2016
|
Imfinzi#
+ selumetinib
|
PD-L1 mAb + MEK inhibitor
|
solid tumours
|
I
|
Q4
2015
|
Imfinzi#
+ tremelimumab
|
PD-L1 mAb + CTLA-4 mAb
|
solid tumours
|
I
|
Q4
2013
|
tremelimumab + MEDI0562#
|
CTLA-4 mAb + humanised OX40 agonist
|
solid tumours
|
I
|
Q2 2016
|
Imfinzi#
+ azacitidine
|
PD-L1 mAb + azacitidine
|
myelodysplastic syndrome
|
I
|
Q2 2016
|
Imfinzi#
+ MEDI0457#
|
PD-L1 mAb + DNA HPV vaccine
|
HNSCC
|
I
|
Q3 2017
|
Lynparza# + AZD6738
|
PARP inhibitor + ATR inhibitor
|
gastric cancer
|
II
|
Q3
2016
|
Lynparza# + AZD1775#
|
PARP inhibitor + Wee1 inhibitor
|
solid tumours
|
I
|
Q3 2015
|
Lynparza# + Imfinzi
MEDIOLA
|
PARP inhibitor + PD-L1 mAb
|
solid tumours
|
II
|
Q2 2016
|
Tagrisso +
(selumetinib#
or savolitinib#)
TATTON
|
EGFR inhibitor + (MEK inhibitor or MET inhibitor)
|
advanced EGFRm NSCLC
|
II
|
Q2
2016
|
Tagrisso BLOOM
|
EGFR
inhibitor
|
CNS metastases in advanced EGFRm NSCLC
|
II
|
Q4
2015
|
AZD1775#
+ chemotherapy
|
Wee1 inhibitor + chemotherapy
|
ovarian cancer
|
II
|
Q4 2012
|
AZD1775#
|
Wee1 inhibitor
|
solid tumours
|
II
|
Q1 2016
|
vistusertib
|
mTOR inhibitor
|
solid tumours
|
II
|
Q1
2013
|
AZD5363#
|
AKT inhibitor
|
breast cancer
|
II
|
Q1
2014
|
AZD4547
|
FGFR inhibitor
|
solid tumours
|
II
|
Q4
2011
|
MEDI-573#
|
IGF mAb
|
metastatic breast cancer
|
II
|
Q2
2012
|
AZD0156
|
ATM inhibitor
|
solid tumours
|
I
|
Q4
2015
|
AZD2811#
|
Aurora B inhibitor
|
solid tumours
|
I
|
Q4
2015
|
AZD4635
|
A2aR inhibitor
|
solid tumours
|
I
|
Q2 2016
|
AZD4785
|
KRAS inhibitor
|
solid tumours
|
I
|
Q2
2017
|
AZD6738
|
ATR inhibitor
|
solid tumours
|
I
|
Q4
2013
|
AZD8186
|
PI3k inhibitor
|
solid tumours
|
I
|
Q2
2013
|
AZD9496
|
selective oestrogen receptor degrader
|
oestrogen receptor +ve breast cancer
|
I
|
Q4 2014
|
MEDI-565#
|
CEA BiTE mAb
|
solid tumours
|
I
|
Q1
2011
|
MEDI0562#
|
humanised OX40 agonist
|
solid tumours
|
I
|
Q1 2015
|
MEDI0680
|
PD-1 mAb
|
solid tumours
|
I
|
Q4
2013
|
MEDI1873
|
GITR agonist fusion protein
|
solid tumours
|
I
|
Q4
2015
|
MEDI3726#
|
PSMA antibody drug conjugate
|
prostate cancer
|
I
|
Q1
2017
|
MEDI4276
|
HER2 bi-specific antibody drug conjugate
|
solid tumours
|
I
|
Q4
2015
|
MEDI5083
|
immune activator
|
solid tumours
|
I
|
Q1
2017
|
MEDI7247
|
antibody drug conjugate
|
haematological malignancies
|
I
|
Q2
2017
|
MEDI9197#
|
TLR 7/8 agonist
|
solid tumours
|
I
|
Q4
2015
|
MEDI9447
|
CD73 mAb
|
solid tumours
|
I
|
Q3
2015
|
CVMD
|
|
|
|
|
verinurad
|
URAT1 inhibitor
|
CKD
|
II
|
Q2
2017
|
MEDI0382
|
GLP-1 /
glucagon dual agonist
|
type-2 diabetes / obesity
|
II
|
Q3
2016
|
MEDI6012
|
LCAT
|
CV disease
|
II
|
Q4
2015
|
AZD4831
|
myeloperoxidase
|
HF with a preserved ejection fraction
|
I
|
Q3
2016
|
AZD5718
|
FLAP
|
coronary artery disease
|
I
|
Q1
2016
|
AZD8601#
|
VEGF-A
|
CV disease
|
I
|
Q1
2017
|
MEDI5884#
|
cholesterol modulation
|
CV disease
|
I
|
Q1
2017
|
Respiratory
|
|
|
|
|
abediterol#
|
LABA
|
asthma / COPD
|
II
|
Q4
2007
|
tezepelumab#
|
TSLP mAb
|
asthma / atopic dermatitis
|
II
|
Q2
2014
|
AZD1419#
|
inhaled TLR9 agonist
|
asthma
|
II
|
Q4
2016
|
AZD7594
|
inhaled SGRM
|
asthma / COPD
|
II
|
Q3
2015
|
AZD8871#
|
MABA
|
COPD
|
II
|
Q1
2017
|
PT010
|
LABA/LAMA/ICS
|
asthma
|
II
|
Q2
2014
|
AZD5634
|
inhaled ENaC
|
cystic fibrosis
|
I
|
Q1
2016
|
AZD7594 + abediterol#
|
inhaled SGRM + LABA
|
asthma / COPD
|
I
|
Q4
2016
|
AZD7986#
|
DPP1
|
COPD
|
I
|
Q4
2014
|
AZD9567
|
oral SGRM
|
rheumatoid arthritis / respiratory
|
I
|
Q4
2015
|
AZD9898#
|
LTC4S
|
asthma
|
I
|
Q2
2017
|
MEDI3506
|
IL-33 mAb
|
COPD
|
I
|
Q2
2017
|
Other
|
|
|
|
|
anifrolumab#
|
IFN-alphaR mAb
|
lupus nephritis
|
II
|
Q4
2015
|
anifrolumab#
|
IFN-alphaR mAb
|
systemic lupus erythematosus (subcutaneous)
|
II
|
Q1
2017
|
inebilizumab#
|
CD19 mAb
|
neuromyelitis optica
|
II
(Orphan
drug US, EU)
|
Q1
2015
|
mavrilimumab#
|
GM-CSFR mAb
|
rheumatoid arthritis
|
II
|
Q1
2010
|
MEDI3902
|
Psl/PcrV bispecific mAb
|
prevention of nosocomial Pseudomonas aeruginosa
pneumonia
|
II
(Fast Track, US)
|
Q2
2016
|
MEDI4893
|
mAb binding to S. aureus toxin
|
prevention of nosocomial Staphylococcus
aureus pneumonia
|
II
(Fast Track, US)
|
Q4
2014
|
MEDI5872#
|
B7RP1 mAb
|
primary
Sjögren's
syndrome
|
II
|
Q3
2015
|
MEDI8852
|
influenza A mAb
|
influenza A treatment
|
II
(Fast
Track, US)
|
Q4
2015
|
MEDI8897#
|
RSV mAb-YTE
|
passive RSV prophylaxis
|
II
(Fast Track, US)
|
Q1
2015
|
AZD0284
|
RORg
|
psoriasis / respiratory
|
I
|
Q4
2016
|
MEDI0700#
|
BAFF/B7RP1 bispecific mAb
|
systemic lupus erythematosus
|
I
|
Q1
2016
|
MEDI1814#
|
amyloid beta mAb
|
Alzheimer's disease
|
I
|
Q2
2014
|
MEDI4920
|
anti-CD40L-Tn3 fusion protein
|
primary Sjögren's syndrome
|
I
|
Q2
2014
|
MEDI7352
|
NGF/TNF bi-specific mAb
|
osteoarthritis pain
|
I
|
Q1
2016
|
MEDI7734
|
ILT7 mAb
|
myositis
|
I
|
Q3
2016
|
MEDI9314
|
IL-4R mAb
|
atopic dermatitis
|
I
|
Q1
2016
|
Compound
|
Mechanism
|
Area Under Investigation
|
Date Commenced Phase
|
Estimated Regulatory Acceptance Date / Submission Status
|
|||
US
|
EU
|
Japan
|
China
|
||||
Oncology
|
|
|
|
|
|
|
|
Faslodex
FALCON
|
oestrogen receptor antagonist
|
1st-line hormone receptor +ve advanced breast cancer
|
|
Approved
|
Approved
|
Approved
|
H2
2017
|
Imfinzi#
PEARL
(China)
|
PD-L1
mAb
|
1st-line
NSCLC
|
Q1
2017
|
|
|
|
2020
|
Lynparza# OlympiAD
|
PARP inhibitor
|
gBRCA metastatic breast cancer
|
Q2
2014
|
Accepted
(Priority
Review)
|
H1
2018
|
Accepted
(Orphan drug
designation, Priority Review)
|
H2
2018
|
Lynparza#SOLO-2
|
PARP inhibitor
|
2nd-line or greater BRCAm PSR ovarian cancer, maintenance
monotherapy
|
Q3
2013
|
Approved
(Priority
Review)
|
Accepted
|
Accepted
(Orphan drug
designation)
|
H1
2018
|
Lynparza#SOLO-1
|
PARP inhibitor
|
1st-line BRCAm ovarian cancer
|
Q3
2013
|
H2
2018
|
H2
2018
|
H2
2018
|
2019
|
Lynparza#SOLO-3
|
PARP inhibitor
|
gBRCA PSR ovarian cancer
|
Q1
2015
|
H2
2018
|
|
|
|
Lynparza#POLO
|
PARP inhibitor
|
pancreatic cancer
|
Q1
2015
|
2019
|
2019
|
|
|
Lynparza#
PROfound
|
PARP inhibitor
|
prostate cancer
|
Q1
2017
|
2020
(Breakthrough
Therapy Designation)
|
2020
|
2020
|
2020
|
Lynparza#
OlympiA
|
PARP inhibitor
|
gBRCA adjuvant breast cancer
|
Q2
2014
|
2020
|
2020
|
2020
|
|
Tagrisso
FLAURA
|
EGFR inhibitor
|
1st-line advanced EGFRm NSCLC
|
Q1
2015
|
H2
2017
(Breakthrough
Therapy designation)
|
H2
2017
|
H2
2017
|
2018
|
Tagrisso
ADAURA
|
EGFR inhibitor
|
adjuvant EGFRm NSCLC
|
Q4
2015
|
2022
|
2022
|
2022
|
2022
|
CVMD
|
|
|
|
|
|
||
Brilinta1
THEMIS
|
P2Y12 receptor antagonist
|
CV outcomes trial in patients with type-2 diabetes and coronary
artery disease without a previous history of MI or stroke
|
Q1
2014
|
2019
|
2019
|
2019
|
2020
|
Brilinta1
HESTIA
|
P2Y12 receptor antagonist
|
prevention of vaso-occlusive crises in paediatric patients with
sickle cell disease
|
Q1
2014
|
2021
|
2021
|
|
|
Kombiglyze XR/Komboglyze2
|
DPP-4 inhibitor / metformin FDC
|
type-2 diabetes
|
|
Launched
|
Launched
|
|
Launched
|
Farxiga3DECLARE-TIMI
58
|
SGLT2 inhibitor
|
CV outcomes trial in patients with type-2 diabetes
|
Q2
2013
|
2019
|
2019
|
|
|
Farxiga3
|
SGLT2 inhibitor
|
type-1 diabetes
|
Q4
2014
|
H2
2018
|
H1
2018
|
H2
2018
|
|
Farxiga3
|
SGLT2 inhibitor
|
worsening HF or CV death in patients with chronic HF
|
Q1
2017
|
2020
|
2020
|
2020
|
2020
|
Farxiga3
|
SGLT2 inhibitor
|
renal outcomes and CV mortality in patients with
CKD
|
Q1
2017
|
2021
|
2021
|
N/A
|
2021
|
Xigduo XR/
Xigduo4
|
SGLT2 inhibitor/ metformin FDC
|
type-2 diabetes
|
|
Launched
|
Launched
|
|
2020
|
Qtern
|
DPP-4 inhibitor / SGLT2 inhibitor FDC
|
type-2 diabetes
|
|
Approved
|
Launched
|
|
|
BydureonBCise (autoinjector)
|
GLP-1 receptor agonist
|
type-2 diabetes
|
Q1
2013
|
Approved
|
Accepted
|
|
|
Bydureon EXSCEL
|
GLP-1 receptor agonist
|
type-2 diabetes outcomes trial
|
Q2
2010
|
H2
2017
|
H2
2017
|
|
H2
2018
|
saxagliptin/
dapagliflozin/
metformin
|
DPP-4 inhibitor / SGLT2 inhibitor
|
type-2 diabetes
|
Q2 2017
|
H1 2018
|
H1 2018
|
|
|
Epanova
STRENGTH
|
omega-3 carboxylic acids
|
CV outcomes trial in statin-treated patients at high CV risk, with
persistent hypertriglyceridae-mia plus low
HDL-cholesterol
|
Q4
2014
|
2020
|
2020
|
2020
|
2020
|
Respiratory
|
|
|
|
|
|
|
|
Symbicort
SYGMA
|
ICS/LABA
|
as-needed use in mild asthma
|
Q4
2014
|
|
2018
|
|
2019
|
Duaklir Genuair#
|
LAMA/LABA
|
COPD
|
|
H1
2018
|
Launched
|
|
2019
|
Other
|
|
|
|
|
|
|
|
Nexium
|
proton-pump inhibitor
|
stress ulcer prophylaxis
|
|
|
|
|
Accepted
|
Nexium
|
proton-pump inhibitor
|
paediatrics
|
|
Launched
|
Launched
|
Accepted
|
|
linaclotide#
|
GC-C receptor peptide agonist
|
irritable bowel syndrome with constipation(IBS-C)
|
|
|
|
|
Accepted
|
NME / Line Extension
|
Compound
|
Reason for Discontinuation
|
Area Under Investigation
|
NME
|
MEDI8111
|
strategic
|
trauma / bleeding
|
Compound
|
Mechanism
|
Area Under Investigation
|
Completed/
Divested
|
Estimated Regulatory Submission Acceptance
|
|||
US
|
EU
|
Japan
|
China
|
||||
AZD9150
|
STAT3
inhibitor
|
haematological
malignancies
|
Completed
|
-
|
-
|
-
|
-
|
For the
nine months ended 30
September
|
|
2017
$m
|
|
2016
$m
|
Product
sales
|
|
14,665
|
|
16,059
|
Externalisation
revenue
|
|
2,023
|
|
1,358
|
Total revenue
|
|
16,688
|
|
17,417
|
Cost of
sales
|
|
(3,093)
|
|
(2,966)
|
Gross profit
|
|
13,595
|
|
14,451
|
Distribution
costs
|
|
(225)
|
|
(243)
|
Research
and development expense
|
|
(4,206)
|
|
(4,347)
|
Selling,
general and administrative costs
|
|
(7,155)
|
|
(8,027)
|
Other
operating income and expense
|
|
982
|
|
535
|
Operating profit
|
|
2,991
|
|
2,369
|
Finance
income
|
|
71
|
|
44
|
Finance
expense
|
|
(1,199)
|
|
(1,022)
|
Share
of after tax losses in associates and joint ventures
|
|
(43)
|
|
(22)
|
Profit before tax
|
|
1,820
|
|
1,369
|
Taxation
|
|
(213)
|
|
220
|
Profit for the period
|
|
1,607
|
|
1,589
|
|
|
|
|
|
Other comprehensive income/(loss)
|
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
|
(146)
|
|
(1,127)
|
Tax on
items that will not be reclassified to profit or loss
|
|
23
|
|
256
|
|
|
(123)
|
|
(871)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
|
Foreign
exchange arising on consolidation
|
|
531
|
|
(690)
|
Foreign
exchange arising on designating borrowings in net investment
hedges
|
|
622
|
|
(194)
|
Fair
value movements on cash flow hedges
|
|
226
|
|
(26)
|
Fair
value movements on cash flow hedges transferred to profit or
loss
|
|
(281)
|
|
41
|
Fair
value movements on derivatives designated in net investment
hedges
|
|
(39)
|
|
(96)
|
Amortisation
of loss on cash flow hedge
|
|
1
|
|
1
|
Net
available for sale (losses)/gains taken to equity
|
|
(36)
|
|
126
|
Tax on
items that may be reclassified subsequently to profit or
loss
|
|
(125)
|
|
63
|
|
|
899
|
|
(775)
|
Other comprehensive income/(loss) for the period, net of
tax
|
|
776
|
|
(1,646)
|
Total comprehensive income/(loss) for the period
|
|
2,383
|
|
(57)
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
1,700
|
|
1,657
|
Non-controlling
interests
|
|
(93)
|
|
(68)
|
|
|
1,607
|
|
1,589
|
|
|
|
|
|
Total comprehensive income/(loss) attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
2,476
|
|
12
|
Non-controlling
interests
|
|
(93)
|
|
(69)
|
|
|
2,383
|
|
(57)
|
|
|
|
|
|
Basic
earnings per $0.25 Ordinary Share
|
|
$1.34
|
|
$1.31
|
Diluted
earnings per $0.25 Ordinary Share
|
|
$1.34
|
|
$1.31
|
Weighted
average number of Ordinary Shares in issue (millions)
|
|
1,266
|
|
1,265
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
|
1,266
|
|
1,266
|
For the
quarter ended 30
September
|
|
2017
$m
|
|
2016
$m
|
Product
sales
|
|
4,882
|
|
5,025
|
Externalisation
revenue
|
|
1,350
|
|
674
|
Total revenue
|
|
6,232
|
|
5,699
|
Cost of
sales
|
|
(1,249)
|
|
(900)
|
Gross profit
|
|
4,983
|
|
4,799
|
Distribution
costs
|
|
(76)
|
|
(76)
|
Research
and development expense
|
|
(1,404)
|
|
(1,402)
|
Selling,
general and administrative costs
|
|
(2,497)
|
|
(2,403)
|
Other
operating income and expense
|
|
143
|
|
110
|
Operating profit
|
|
1,149
|
|
1,028
|
Finance
income
|
|
32
|
|
13
|
Finance
expense
|
|
(418)
|
|
(355)
|
Share
of after tax losses in associates and joint ventures
|
|
(17)
|
|
(10)
|
Profit before tax
|
|
746
|
|
676
|
Taxation
|
|
(97)
|
|
319
|
Profit for the period
|
|
649
|
|
995
|
|
|
|
|
|
Other comprehensive income/(loss)
|
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
|
125
|
|
(285)
|
Tax on
items that will not be reclassified to profit or loss
|
|
(48)
|
|
21
|
|
|
77
|
|
(264)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
|
Foreign
exchange arising on consolidation
|
|
154
|
|
(167)
|
Foreign
exchange arising on designating borrowings in net investment
hedges
|
|
239
|
|
(127)
|
Fair
value movements on cash flow hedges
|
|
99
|
|
77
|
Fair
value movements on cash flow hedges transferred to profit or
loss
|
|
(81)
|
|
(19)
|
Fair
value movements on derivatives designated in net investment
hedges
|
|
(4)
|
|
(17)
|
Net
available for sale gains taken to equity
|
|
58
|
|
162
|
Tax on
items that may be reclassified subsequently to profit or
loss
|
|
(55)
|
|
(12)
|
|
|
410
|
|
(103)
|
Other comprehensive income/(loss) for the period, net of
tax
|
|
487
|
|
(367)
|
Total comprehensive income for the period
|
|
1,136
|
|
628
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
686
|
|
1,014
|
Non-controlling
interests
|
|
(37)
|
|
(19)
|
|
|
649
|
|
995
|
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
1,173
|
|
648
|
Non-controlling
interests
|
|
(37)
|
|
(20)
|
|
|
1,136
|
|
628
|
|
|
|
|
|
Basic
earnings per $0.25 Ordinary Share
|
|
$0.54
|
|
$0.80
|
Diluted
earnings per $0.25 Ordinary Share
|
|
$0.54
|
|
$0.80
|
Weighted
average number of Ordinary Shares in issue (millions)
|
|
1,266
|
|
1,265
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
|
1,267
|
|
1,266
|
|
|
At
30 Sep
2017
$m
|
|
At
31 Dec
2016
$m
|
|
Restated*
At
30 Sep
2016
$m
|
ASSETS
Non-current assets
|
|
|
|
|
|
|
Property,
plant and equipment
|
|
7,329
|
|
6,848
|
|
6,690
|
Goodwill
|
|
11,841
|
|
11,658
|
|
11,756
|
Intangible
assets
|
|
27,124
|
|
27,586
|
|
28,507
|
Derivative
financial instruments
|
|
440
|
|
343
|
|
278
|
Investments
in associates and joint ventures
|
|
78
|
|
99
|
|
95
|
Other
investments
|
|
1,004
|
|
727
|
|
715
|
Other
receivables
|
|
953
|
|
901
|
|
681
|
Deferred
tax assets
|
|
2,184
|
|
1,102
|
|
1,584
|
|
|
50,953
|
|
49,264
|
|
50,306
|
Current assets
|
|
|
|
|
|
|
Inventories
|
|
3,162
|
|
2,334
|
|
2,420
|
Assets
held for sale
|
|
-
|
|
-
|
|
332
|
Trade
and other receivables
|
|
4,540
|
|
4,573
|
|
5,449
|
Other
investments
|
|
1,175
|
|
884
|
|
909
|
Derivative
financial instruments
|
|
-
|
|
27
|
|
26
|
Income
tax receivable
|
|
721
|
|
426
|
|
640
|
Cash
and cash equivalents
|
|
4,036
|
|
5,018
|
|
3,090
|
|
|
13,634
|
|
13,262
|
|
12,866
|
Total assets
|
|
64,587
|
|
62,526
|
|
63,172
|
LIABILITIES
Current liabilities
|
|
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(941)
|
|
(2,307)
|
|
(2,939)
|
Trade
and other payables
|
|
(10,832)
|
|
(10,486)
|
|
(9,961)
|
Derivative
financial instruments
|
|
(10)
|
|
(18)
|
|
(12)
|
Provisions
|
|
(1,167)
|
|
(1,065)
|
|
(936)
|
Income
tax payable
|
|
(1,513)
|
|
(1,380)
|
|
(1,534)
|
|
|
(14,463)
|
|
(15,256)
|
|
(15,382)
|
Non-current liabilities
|
|
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
(16,911)
|
|
(14,501)
|
|
(14,744)
|
Derivative
financial instruments
|
|
(3)
|
|
(117)
|
|
(25)
|
Deferred
tax liabilities
|
|
(5,079)
|
|
(3,956)
|
|
(4,001)
|
Retirement
benefit obligations
|
|
(2,490)
|
|
(2,186)
|
|
(2,870)
|
Provisions
|
|
(387)
|
|
(353)
|
|
(396)
|
Other
payables
|
|
(9,807)
|
|
(9,488)
|
|
(10,842)
|
|
|
(34,677)
|
|
(30,601)
|
|
(32,878)
|
Total liabilities
|
|
(49,140)
|
|
(45,857)
|
|
(48,260)
|
Net assets
|
|
15,447
|
|
16,669
|
|
14,912
|
EQUITY
|
|
|
|
|
|
|
Capital and reserves attributable to equity holders of the
Company
|
|
|
|
|
|
|
Share
capital
|
|
316
|
|
316
|
|
316
|
Share
premium account
|
|
4,381
|
|
4,351
|
|
4,344
|
Other
reserves
|
|
2,027
|
|
2,047
|
|
2,031
|
Retained
earnings
|
|
7,001
|
|
8,140
|
|
6,381
|
|
|
13,725
|
|
14,854
|
|
13,072
|
Non-controlling interests
|
|
1,722
|
|
1,815
|
|
1,840
|
Total equity
|
|
15,447
|
|
16,669
|
|
14,912
|
For the
nine months ended 30
September
|
|
2017
$m
|
|
2016
$m
|
|
Cash flows from operating activities
|
|
|
|
|
|
Profit
before tax
|
|
1,820
|
|
1,369
|
|
Finance
income and expense
|
|
1,128
|
|
978
|
|
Share
of after tax losses in associates and joint ventures
|
|
43
|
|
22
|
|
Depreciation,
amortisation and impairment
|
|
1,929
|
|
1,767
|
|
Increase
in working capital and short-term provisions
|
|
(228)
|
|
(472)
|
|
Gains
on disposal of intangible assets
|
|
(735)
|
|
(198)
|
|
Fair
value movements on contingent consideration arising from business
combinations
|
|
(62)
|
|
132
|
|
Non-cash
and other movements
|
|
(322)
|
|
(479)
|
|
Cash generated from operations
|
|
3,573
|
|
3,119
|
|
Interest
paid
|
|
(519)
|
|
(489)
|
|
Tax
paid
|
|
(473)
|
|
(445)
|
|
Net cash inflow from operating activities
|
|
2,581
|
|
2,185
|
|
Cash flows from investing activities
|
|
|
|
|
|
Movement
in short-term investments and fixed deposits
|
|
(288)
|
|
(165)
|
|
Purchase
of property, plant and equipment
|
|
(849)
|
|
(912)
|
|
Disposal
of property, plant and equipment
|
|
57
|
|
47
|
|
Purchase
of intangible assets
|
|
(220)
|
|
(761)
|
|
Disposal
of intangible assets
|
|
894
|
|
117
|
|
Purchase
of non-current asset investments
|
|
(91)
|
|
(210)
|
|
Disposal
of non-current asset investments
|
|
14
|
|
-
|
|
Payments
to joint ventures
|
|
(11)
|
|
(19)
|
|
Upfront
payments on business combinations
|
|
-
|
|
(2,564)
|
|
Payment
of contingent consideration from business combinations
|
|
(310)
|
|
(197)
|
|
Interest
received
|
|
118
|
|
105
|
|
Payments
made by subsidiaries to non-controlling interests
|
|
-
|
|
(13)
|
|
Net cash outflow from investing activities
|
|
(686)
|
|
(4,572)
|
|
Net cash inflow/(outflow) before financing activities
|
|
1,895
|
|
(2,387)
|
|
Cash flows from financing activities
|
|
|
|
|
|
Proceeds
from issue of share capital
|
|
30
|
|
40
|
|
Issue
of loans
|
|
1,988
|
|
2,483
|
|
Repayment
of loans
|
|
(1,750)
|
|
-
|
|
Dividends
paid
|
|
(3,519)
|
|
(3,561)
|
|
Hedge
contracts relating to dividend payments
|
|
(20)
|
|
18
|
|
Repayment
of obligations under finance leases
|
|
(14)
|
|
(12)
|
|
Movement
in short-term borrowings
|
|
361
|
|
12
|
|
Net cash outflow from financing activities
|
|
(2,924)
|
|
(1,020)
|
|
Net
decrease in cash and cash equivalents in the period
|
|
(1,029)
|
|
(3,407)
|
|
Cash
and cash equivalents at the beginning of the period
|
|
4,924
|
|
6,051
|
|
Exchange
rate effects
|
|
(71)
|
|
43
|
|
Cash and cash equivalents at the end of the period
|
|
3,824
|
|
2,687
|
|
Cash and cash equivalents consists of:
|
|
|
|
|
|
Cash
and cash equivalents
|
|
4,036
|
|
3,090
|
|
Overdrafts
|
|
(212)
|
|
(403)
|
|
|
|
3,824
|
|
2,687
|
|
|
|
|
|
|
|
|
|
Sharecapital$m
|
|
Sharepremiumaccount$m
|
|
Otherreserves*$m
|
|
Retainedearnings$m
|
|
Total $m
|
|
Non-controllinginterests$m
|
|
Totalequity$m
|
At
1 Jan 2016
|
|
316
|
|
4,304
|
|
2,036
|
|
11,834
|
|
18,490
|
|
19
|
|
18,509
|
Profit
for the period
|
|
-
|
|
-
|
|
-
|
|
1,657
|
|
1,657
|
|
(68)
|
|
1,589
|
Other
comprehensive income
|
|
-
|
|
-
|
|
-
|
|
(1,645)
|
|
(1,645)
|
|
(1)
|
|
(1,646)
|
Transfer to other
reserves
|
|
-
|
|
-
|
|
(5)
|
|
5
|
|
-
|
|
-
|
|
-
|
Transactions
with owners:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
|
-
|
|
-
|
|
(3,540)
|
|
(3,540)
|
|
-
|
|
(3,540)
|
Dividends paid by
subsidiary to non-controlling interest
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
(13)
|
|
(13)
|
Acerta
put option
|
|
-
|
|
-
|
|
-
|
|
(1,825)
|
|
(1,825)
|
|
-
|
|
(1,825)
|
Changes
in non-controlling interest
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
1,903
|
|
1,903
|
Issue
of Ordinary Shares
|
|
-
|
|
40
|
|
-
|
|
-
|
|
40
|
|
-
|
|
40
|
Share-based
payments
|
|
-
|
|
-
|
|
-
|
|
(105)
|
|
(105)
|
|
-
|
|
(105)
|
Net
movement
|
|
-
|
|
40
|
|
(5)
|
|
(5,453)
|
|
(5,418)
|
|
1,821
|
|
(3,597)
|
At
30 Sep 2016
|
|
316
|
|
4,344
|
|
2,031
|
|
6,381
|
|
13,072
|
|
1,840
|
|
14,912
|
|
|
Sharecapital$m
|
|
Sharepremiumaccount$m
|
|
Otherreserves*$m
|
|
Retainedearnings$m
|
|
Total $m
|
|
Non-controllinginterests$m
|
|
Totalequity$m
|
At
1 Jan 2017
|
|
316
|
|
4,351
|
|
2,047
|
|
8,140
|
|
14,854
|
|
1,815
|
|
16,669
|
Profit
for the period
|
|
-
|
|
-
|
|
-
|
|
1,700
|
|
1,700
|
|
(93)
|
|
1,607
|
Other
comprehensive income
|
|
-
|
|
-
|
|
-
|
|
776
|
|
776
|
|
-
|
|
776
|
Transfer to other
reserves
|
|
-
|
|
-
|
|
(20)
|
|
20
|
|
-
|
|
-
|
|
-
|
Transactions
with owners:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
|
-
|
|
-
|
|
(3,543)
|
|
(3,543)
|
|
-
|
|
(3,543)
|
Issue
of Ordinary Shares
|
|
-
|
|
30
|
|
-
|
|
-
|
|
30
|
|
-
|
|
30
|
Share-based
payments
|
|
-
|
|
-
|
|
-
|
|
(92)
|
|
(92)
|
|
-
|
|
(92)
|
Net
movement
|
|
-
|
|
30
|
|
(20)
|
|
(1,139)
|
|
(1,129)
|
|
(93)
|
|
(1,222)
|
At
30 Sep 2017
|
|
316
|
|
4,381
|
|
2,027
|
|
7,001
|
|
13,725
|
|
1,722
|
|
15,447
|
|
|
YTD
2017$m
|
|
YTD
2016$m
|
|
Q3
2017$m
|
|
Q3
2016$m
|
Cost of
sales
|
|
128
|
|
87
|
|
47
|
|
59
|
Research and
development expense
|
|
177
|
|
146
|
|
35
|
|
39
|
Selling, general
and administrative costs
|
|
265
|
|
504
|
|
68
|
|
176
|
Other
operating income and expense
|
|
75
|
|
(24)
|
|
(1)
|
|
(24)
|
Total
|
|
645
|
|
713
|
|
149
|
|
250
|
|
|
At 1 Jan
2017
$m
|
|
Cash
Flow
$m
|
|
Non-cash
&
Other
$m
|
|
Exchange
Movements
$m
|
|
At
30 Sep
2017
$m
|
Loans
due after one year
|
|
(14,495)
|
|
(1,988)
|
|
(7)
|
|
(420)
|
|
(16,910)
|
Finance
leases due after one year
|
|
(6)
|
|
-
|
|
5
|
|
-
|
|
(1)
|
Total
long-term debt
|
|
(14,501)
|
|
(1,988)
|
|
(2)
|
|
(420)
|
|
(16,911)
|
|
|
|
|
|
|
|
|
|
|
|
Current
instalments of loans
|
|
(1,769)
|
|
1,750
|
|
19
|
|
-
|
|
-
|
Current
instalments of finance leases
|
|
(87)
|
|
14
|
|
63
|
|
(1)
|
|
(11)
|
Total
current debt
|
|
(1,856)
|
|
1,764
|
|
82
|
|
(1)
|
|
(11)
|
|
|
|
|
|
|
|
|
|
|
|
Other
investments - current
|
|
884
|
|
288
|
|
-
|
|
3
|
|
1,175
|
Other
investments - non-current
|
|
14
|
|
66
|
|
-
|
|
-
|
|
80
|
Net
derivative financial instruments
|
|
235
|
|
20
|
|
172
|
|
-
|
|
427
|
Cash
and cash equivalents
|
|
5,018
|
|
(913)
|
|
-
|
|
(69)
|
|
4,036
|
Overdrafts
|
|
(94)
|
|
(116)
|
|
-
|
|
(2)
|
|
(212)
|
Short-term
borrowings
|
|
(357)
|
|
(361)
|
|
-
|
|
-
|
|
(718)
|
|
|
5,700
|
|
(1,016)
|
|
172
|
|
(68)
|
|
4,788
|
Net
debt
|
|
(10,657)
|
|
(1,240)
|
|
252
|
|
(489)
|
|
(12,134)
|
|
|
Diabetes
Alliance
2017
|
|
Other
2017
|
|
Total
2017
|
|
Total
2016
|
|
|
$m
|
|
$m
|
|
$m
|
|
$m
|
At
1 January
|
|
4,240
|
|
1,217
|
|
5,457
|
|
6,411
|
Settlements
|
|
(235)
|
|
(75)
|
|
(310)
|
|
(197)
|
Revaluations
|
|
(71)
|
|
9
|
|
(62)
|
|
132
|
Discount
unwind
|
|
234
|
|
71
|
|
305
|
|
372
|
Foreign
exchange
|
|
-
|
|
-
|
|
-
|
|
2
|
At
30 September
|
|
4,168
|
|
1,222
|
|
5,390
|
|
6,720
|
|
World
|
|
Emerging Markets
|
|
US
|
|
Europe
|
|
Established ROW
|
||||||||||||||
|
YTD 2017
$m
|
|
Actual
%
|
CER
%
|
|
YTD 2017
$m
|
|
Actual
%
|
CER%
|
|
YTD 2017
$m
|
|
Actual
%
|
|
YTD 2017
$m
|
|
Actual
%
|
CER
%
|
|
YTD 2017
$m
|
|
Actual
%
|
CER
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
651
|
|
136
|
138
|
|
85
|
|
n/m
|
n/m
|
|
277
|
|
54
|
|
124
|
|
153
|
157
|
|
165
|
|
n/m
|
n/m
|
Iressa
|
398
|
|
1
|
2
|
|
200
|
|
7
|
8
|
|
27
|
|
69
|
|
80
|
|
(12)
|
(12)
|
|
91
|
|
(10)
|
(9)
|
Lynparza
|
197
|
|
26
|
26
|
|
11
|
|
n/m
|
n/m
|
|
87
|
|
(9)
|
|
94
|
|
68
|
70
|
|
5
|
|
n/m
|
n/m
|
Imfinzi
|
1
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
|
1
|
|
n/m
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faslodex
|
703
|
|
16
|
16
|
|
88
|
|
26
|
23
|
|
368
|
|
15
|
|
194
|
|
15
|
16
|
|
53
|
|
10
|
13
|
Zoladex
|
548
|
|
(6)
|
(5)
|
|
260
|
|
9
|
10
|
|
16
|
|
(41)
|
|
104
|
|
(11)
|
(8)
|
|
168
|
|
(16)
|
(15)
|
Casodex
|
161
|
|
(14)
|
(12)
|
|
78
|
|
(5)
|
(1)
|
|
1
|
|
(50)
|
|
17
|
|
(11)
|
(11)
|
|
65
|
|
(23)
|
(21)
|
Arimidex
|
160
|
|
(9)
|
(6)
|
|
85
|
|
2
|
6
|
|
5
|
|
(58)
|
|
26
|
|
(4)
|
(4)
|
|
44
|
|
(17)
|
(15)
|
Others
|
85
|
|
13
|
16
|
|
21
|
|
5
|
10
|
|
-
|
|
-
|
|
4
|
|
-
|
-
|
|
60
|
|
18
|
20
|
Total Oncology
|
2,904
|
|
18
|
19
|
|
828
|
|
20
|
22
|
|
782
|
|
20
|
|
643
|
|
21
|
23
|
|
651
|
|
12
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CVMD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brilinta
|
780
|
|
29
|
31
|
|
175
|
|
29
|
32
|
|
355
|
|
46
|
|
213
|
|
11
|
13
|
|
37
|
|
16
|
13
|
Farxiga
|
742
|
|
24
|
24
|
|
160
|
|
74
|
72
|
|
339
|
|
4
|
|
171
|
|
26
|
27
|
|
72
|
|
76
|
76
|
Onglyza
|
431
|
|
(25)
|
(25)
|
|
93
|
|
(15)
|
(16)
|
|
217
|
|
(29)
|
|
78
|
|
(24)
|
(23)
|
|
43
|
|
(22)
|
(22)
|
Bydureon
|
427
|
|
(2)
|
(2)
|
|
5
|
|
25
|
25
|
|
343
|
|
(2)
|
|
65
|
|
(13)
|
(12)
|
|
14
|
|
75
|
75
|
Byetta
|
128
|
|
(36)
|
(35)
|
|
9
|
|
(53)
|
(53)
|
|
81
|
|
(36)
|
|
26
|
|
(30)
|
(27)
|
|
12
|
|
(25)
|
(25)
|
Symlin
|
35
|
|
30
|
30
|
|
-
|
|
-
|
-
|
|
35
|
|
30
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Crestor
|
1,771
|
|
(36)
|
(35)
|
|
577
|
|
7
|
10
|
|
246
|
|
(78)
|
|
514
|
|
(22)
|
(21)
|
|
434
|
|
(2)
|
(1)
|
Seloken/Toprol-XL
|
527
|
|
(6)
|
(4)
|
|
437
|
|
9
|
12
|
|
34
|
|
(58)
|
|
48
|
|
(28)
|
(27)
|
|
8
|
|
(20)
|
(20)
|
Atacand
|
227
|
|
(3)
|
(1)
|
|
135
|
|
15
|
19
|
|
17
|
|
(39)
|
|
63
|
|
(15)
|
(15)
|
|
12
|
|
(20)
|
(20)
|
Others
|
259
|
|
(16)
|
(14)
|
|
157
|
|
(14)
|
(9)
|
|
2
|
|
n/m
|
|
69
|
|
(22)
|
(22)
|
|
31
|
|
(18)
|
(18)
|
Total CVMD
|
5,327
|
|
(16)
|
(14)
|
|
1,748
|
|
9
|
12
|
|
1,669
|
|
(36)
|
|
1,247
|
|
(13)
|
(12)
|
|
663
|
|
-
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
2,051
|
|
(9)
|
(8)
|
|
322
|
|
7
|
8
|
|
811
|
|
(15)
|
|
590
|
|
(13)
|
(11)
|
|
328
|
|
6
|
5
|
Pulmicort
|
805
|
|
4
|
7
|
|
571
|
|
14
|
19
|
|
107
|
|
(22)
|
|
66
|
|
(10)
|
(10)
|
|
61
|
|
-
|
2
|
Daliresp/Daxas
|
145
|
|
28
|
28
|
|
4
|
|
n/m
|
n/m
|
|
124
|
|
23
|
|
16
|
|
60
|
60
|
|
1
|
|
-
|
-
|
Tudorza/Eklira
|
108
|
|
(19)
|
(18)
|
|
-
|
|
n/m
|
n/m
|
|
47
|
|
(23)
|
|
55
|
|
(15)
|
(14)
|
|
6
|
|
(14)
|
(14)
|
Duaklir
|
56
|
|
27
|
30
|
|
-
|
|
n/m
|
n/m
|
|
-
|
|
-
|
|
54
|
|
23
|
25
|
|
2
|
|
100
|
100
|
Bevespi
|
8
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
|
8
|
|
n/m
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Others
|
199
|
|
(13)
|
(12)
|
|
68
|
|
(38)
|
(35)
|
|
1
|
|
(86)
|
|
98
|
|
21
|
22
|
|
32
|
|
(3)
|
(3)
|
Total Respiratory
|
3,372
|
|
(5)
|
(3)
|
|
965
|
|
6
|
9
|
|
1,098
|
|
(13)
|
|
879
|
|
(8)
|
(6)
|
|
430
|
|
4
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
1,525
|
|
(1)
|
-
|
|
516
|
|
(5)
|
(2)
|
|
442
|
|
6
|
|
176
|
|
(7)
|
(7)
|
|
391
|
|
1
|
2
|
Synagis
|
453
|
|
21
|
21
|
|
-
|
|
-
|
-
|
|
182
|
|
6
|
|
271
|
|
33
|
33
|
|
-
|
|
-
|
-
|
Losec/Prilosec
|
202
|
|
(7)
|
(5)
|
|
104
|
|
(1)
|
3
|
|
9
|
|
29
|
|
57
|
|
(10)
|
(10)
|
|
32
|
|
(24)
|
(24)
|
Seroquel XR
|
224
|
|
(64)
|
(64)
|
|
47
|
|
(11)
|
(11)
|
|
103
|
|
(77)
|
|
61
|
|
(42)
|
(42)
|
|
13
|
|
(7)
|
(7)
|
Movantik/Moventig
|
92
|
|
42
|
42
|
|
-
|
|
n/m
|
n/m
|
|
91
|
|
42
|
|
1
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
FluMist/Fluenz
|
20
|
|
(46)
|
(46)
|
|
-
|
|
n/m
|
n/m
|
|
-
|
|
(100)
|
|
18
|
|
(14)
|
(14)
|
|
2
|
|
-
|
-
|
Others
|
546
|
|
(40)
|
(39)
|
|
311
|
|
(22)
|
(23)
|
|
23
|
|
(77)
|
|
107
|
|
(56)
|
(51)
|
|
105
|
|
(39)
|
(42)
|
Total Other
|
3,062
|
|
(19)
|
(18)
|
|
978
|
|
(11)
|
(10)
|
|
850
|
|
(30)
|
|
691
|
|
(16)
|
(15)
|
|
543
|
|
(12)
|
(12)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL PRODUCT SALES
|
14,665
|
|
(9)
|
(8)
|
|
4,519
|
|
5
|
7
|
|
4,399
|
|
(23)
|
|
3,460
|
|
(7)
|
(6)
|
|
2,287
|
|
1
|
1
|
|
World
|
|
Emerging Markets
|
|
US
|
|
Europe
|
|
Established ROW
|
||||||||||||||||
|
Q3 2017
$m
|
|
Actual
%
|
CER
%
|
|
Q3 2017
$m
|
|
Actual
%
|
CER%
|
|
Q3 2017
$m
|
|
Actual
%
|
|
Q3 2017
$m
|
|
Actual
%
|
CER
%
|
|
Q3 2017
$m
|
|
Actual
%
|
CER
%
|
||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Tagrisso
|
248
|
|
86
|
89
|
|
45
|
|
n/m
|
n/m
|
|
97
|
|
26
|
|
48
|
|
100
|
96
|
|
58
|
|
107
|
121
|
||
Iressa
|
137
|
|
10
|
10
|
|
71
|
|
34
|
32
|
|
10
|
|
67
|
|
26
|
|
(13)
|
(13)
|
|
30
|
|
(17)
|
(11)
|
||
Lynparza
|
81
|
|
40
|
36
|
|
6
|
|
n/m
|
n/m
|
|
37
|
|
9
|
|
36
|
|
50
|
54
|
|
2
|
|
n/m
|
n/m
|
||
Imfinzi
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
||
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Faslodex
|
241
|
|
16
|
16
|
|
34
|
|
48
|
52
|
|
127
|
|
15
|
|
61
|
|
9
|
4
|
|
19
|
|
6
|
11
|
||
Zoladex
|
185
|
|
(7)
|
(6)
|
|
92
|
|
8
|
7
|
|
2
|
|
(75)
|
|
37
|
|
-
|
-
|
|
54
|
|
(22)
|
(17)
|
||
Casodex
|
51
|
|
(18)
|
(16)
|
|
22
|
|
(21)
|
(21)
|
|
1
|
|
n/m
|
|
6
|
|
-
|
-
|
|
22
|
|
(21)
|
(18)
|
||
Arimidex
|
54
|
|
(4)
|
(2)
|
|
28
|
|
4
|
4
|
|
2
|
|
-
|
|
9
|
|
-
|
-
|
|
15
|
|
(17)
|
(11)
|
||
Others
|
29
|
|
7
|
15
|
|
8
|
|
14
|
29
|
|
-
|
|
-
|
|
1
|
|
-
|
-
|
|
20
|
|
5
|
11
|
||
Total Oncology
|
1,026
|
|
18
|
19
|
|
306
|
|
35
|
34
|
|
276
|
|
16
|
|
224
|
|
20
|
18
|
|
220
|
|
2
|
8
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
CVMD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Brilinta
|
284
|
|
37
|
36
|
|
54
|
|
20
|
24
|
|
140
|
|
67
|
|
78
|
|
16
|
12
|
|
12
|
|
-
|
(8)
|
||
Farxiga
|
285
|
|
30
|
29
|
|
60
|
|
54
|
56
|
|
133
|
|
13
|
|
66
|
|
40
|
34
|
|
26
|
|
63
|
63
|
||
Onglyza
|
127
|
|
(25)
|
(25)
|
|
30
|
|
-
|
(3)
|
|
58
|
|
(37)
|
|
26
|
|
(10)
|
(10)
|
|
13
|
|
(28)
|
(28)
|
||
Bydureon
|
128
|
|
(12)
|
(12)
|
|
-
|
|
n/m
|
n/m
|
|
100
|
|
(13)
|
|
23
|
|
(8)
|
(8)
|
|
5
|
|
67
|
67
|
||
Byetta
|
39
|
|
(36)
|
(36)
|
|
4
|
|
(20)
|
(20)
|
|
23
|
|
(39)
|
|
8
|
|
(33)
|
(33)
|
|
4
|
|
(33)
|
(33)
|
||
Symlin
|
10
|
|
(9)
|
(9)
|
|
-
|
|
-
|
-
|
|
10
|
|
(9)
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
||
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Crestor
|
580
|
|
(16)
|
(14)
|
|
188
|
|
1
|
3
|
|
93
|
|
(25)
|
|
152
|
|
(31)
|
(32)
|
|
147
|
|
(8)
|
(2)
|
||
Seloken/Toprol-XL
|
160
|
|
(14)
|
(12)
|
|
148
|
|
15
|
16
|
|
4
|
|
(86)
|
|
6
|
|
(74)
|
(74)
|
|
2
|
|
(60)
|
(60)
|
||
Atacand
|
80
|
|
10
|
11
|
|
50
|
|
39
|
44
|
|
5
|
|
(29)
|
|
21
|
|
(16)
|
(20)
|
|
4
|
|
(20)
|
(20)
|
||
Others
|
80
|
|
(6)
|
(5)
|
|
47
|
|
-
|
2
|
|
2
|
|
n/m
|
|
20
|
|
(20)
|
(20)
|
|
11
|
|
(15)
|
(15)
|
||
Total CVMD
|
1,773
|
|
(4)
|
(4)
|
|
581
|
|
12
|
14
|
|
568
|
|
(8)
|
|
400
|
|
(15)
|
(18)
|
|
224
|
|
(5)
|
(2)
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Symbicort
|
668
|
|
(4)
|
(4)
|
|
109
|
|
17
|
17
|
|
257
|
|
(7)
|
|
191
|
|
(10)
|
(12)
|
|
111
|
|
(3)
|
(1)
|
||
Pulmicort
|
242
|
|
8
|
9
|
|
175
|
|
15
|
16
|
|
29
|
|
(9)
|
|
18
|
|
(5)
|
(11)
|
|
20
|
|
(5)
|
-
|
||
Daliresp/Daxas
|
53
|
|
26
|
26
|
|
1
|
|
n/m
|
n/m
|
|
45
|
|
29
|
|
7
|
|
17
|
17
|
|
-
|
|
n/m
|
n/m
|
||
Tudorza/Eklira
|
37
|
|
(21)
|
(21)
|
|
-
|
|
-
|
-
|
|
18
|
|
(10)
|
|
17
|
|
(29)
|
(29)
|
|
2
|
|
(33)
|
(33)
|
||
Duaklir
|
21
|
|
50
|
43
|
|
-
|
|
n/m
|
n/m
|
|
-
|
|
-
|
|
20
|
|
25
|
19
|
|
1
|
|
n/m
|
n/m
|
||
Bevespi
|
4
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
|
4
|
|
n/m
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
||
Others
|
67
|
|
(22)
|
(22)
|
|
21
|
|
(45)
|
(45)
|
|
(1)
|
|
n/m
|
|
37
|
|
19
|
19
|
|
10
|
|
(41)
|
(41)
|
||
Total Respiratory
|
1,092
|
|
(2)
|
(2)
|
|
306
|
|
9
|
10
|
|
352
|
|
(3)
|
|
290
|
|
(6)
|
(8)
|
|
144
|
|
(8)
|
(6)
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Nexium
|
469
|
|
(9)
|
(7)
|
|
172
|
|
(2)
|
-
|
|
103
|
|
(17)
|
|
56
|
|
(11)
|
(16)
|
|
138
|
|
(9)
|
(4)
|
||
Synagis
|
153
|
|
47
|
47
|
|
-
|
|
-
|
-
|
|
15
|
|
88
|
|
138
|
|
44
|
44
|
|
-
|
|
-
|
-
|
||
Losec/Prilosec
|
66
|
|
(8)
|
(8)
|
|
34
|
|
3
|
6
|
|
1
|
|
(50)
|
|
19
|
|
(14)
|
(18)
|
|
12
|
|
(20)
|
(20)
|
||
Seroquel XR
|
62
|
|
(67)
|
(68)
|
|
15
|
|
(17)
|
(22)
|
|
26
|
|
(81)
|
|
18
|
|
(40)
|
(40)
|
|
3
|
|
(25)
|
(25)
|
||
Movantik/Moventig
|
30
|
|
20
|
20
|
|
-
|
|
n/m
|
n/m
|
|
29
|
|
21
|
|
1
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
||
FluMist/Fluenz
|
20
|
|
(23)
|
(23)
|
|
-
|
|
n/m
|
n/m
|
|
-
|
|
(100)
|
|
18
|
|
(14)
|
(14)
|
|
2
|
|
-
|
-
|
||
Others
|
191
|
|
(30)
|
(29)
|
|
101
|
|
(28)
|
(23)
|
|
16
|
|
(32)
|
|
24
|
|
(65)
|
(69)
|
|
50
|
|
11
|
11)
|
||
Total Other
|
991
|
|
(18)
|
(17)
|
|
322
|
|
(13)
|
(10)
|
|
190
|
|
(41)
|
|
274
|
|
(8)
|
(10)
|
|
205
|
|
(6)
|
(2)
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
TOTAL PRODUCT SALES
|
4,882
|
|
(3)
|
(2)
|
|
1,515
|
|
9
|
10
|
|
1,386
|
|
(10)
|
|
1,188
|
|
(6)
|
(8)
|
|
793
|
|
(4)
|
-
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 2017
$m
|
|
Actual
%
|
CER
%
|
|
Q2 2017
$m
|
|
Actual
%
|
CER%
|
|
Q3 2017
$m
|
|
Actual
%
|
CER
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
171
|
|
16
|
19
|
|
232
|
|
36
|
34
|
|
248
|
|
7
|
5
|
Iressa
|
124
|
|
5
|
8
|
|
137
|
|
10
|
9
|
|
137
|
|
-
|
(1)
|
Lynparza
|
57
|
|
(8)
|
(6)
|
|
59
|
|
4
|
2
|
|
81
|
|
37
|
33
|
Imfinzi
|
-
|
|
-
|
-
|
|
1
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faslodex
|
214
|
|
(4)
|
(3)
|
|
248
|
|
16
|
15
|
|
241
|
|
(3)
|
(5)
|
Zoladex
|
185
|
|
(21)
|
(12)
|
|
178
|
|
(4)
|
(5)
|
|
185
|
|
4
|
2
|
Casodex
|
56
|
|
(7)
|
(2)
|
|
54
|
|
(4)
|
(3)
|
|
51
|
|
(6)
|
(9)
|
Arimidex
|
52
|
|
(9)
|
(7)
|
|
54
|
|
4
|
4
|
|
54
|
|
-
|
(2)
|
Others
|
26
|
|
(10)
|
(3)
|
|
30
|
|
15
|
7
|
|
29
|
|
(3)
|
(3)
|
Total Oncology
|
885
|
|
(5)
|
-
|
|
993
|
|
12
|
11
|
|
1,026
|
|
3
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CVMD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brilinta
|
224
|
|
(5)
|
(4)
|
|
272
|
|
21
|
20
|
|
284
|
|
4
|
3
|
Farxiga
|
207
|
|
(13)
|
(13)
|
|
250
|
|
21
|
20
|
|
285
|
|
14
|
11
|
Onglyza
|
154
|
|
3
|
3
|
|
150
|
|
(3)
|
(3)
|
|
127
|
|
(15)
|
(17)
|
Bydureon
|
153
|
|
8
|
8
|
|
146
|
|
(5)
|
(5)
|
|
128
|
|
(12)
|
(14)
|
Byetta
|
46
|
|
(16)
|
(16)
|
|
43
|
|
(7)
|
(7)
|
|
39
|
|
(9)
|
(9)
|
Symlin
|
14
|
|
-
|
-
|
|
11
|
|
(21)
|
(21)
|
|
10
|
|
(9)
|
(9)
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Crestor
|
631
|
|
-
|
3
|
|
560
|
|
(11)
|
(12)
|
|
580
|
|
4
|
2
|
Seloken/Toprol-XL
|
186
|
|
4
|
6
|
|
181
|
|
(3)
|
(4)
|
|
160
|
|
(12)
|
(14)
|
Atacand
|
75
|
|
(7)
|
(6)
|
|
72
|
|
(4)
|
(5)
|
|
80
|
|
11
|
8
|
Others
|
89
|
|
3
|
12
|
|
90
|
|
1
|
(3)
|
|
80
|
|
(11)
|
(12)
|
Total CVMD
|
1,779
|
|
(2)
|
-
|
|
1,775
|
|
-
|
(1)
|
|
1,773
|
|
-
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
677
|
|
(9)
|
(7)
|
|
706
|
|
4
|
3
|
|
668
|
|
(5)
|
(7)
|
Pulmicort
|
337
|
|
17
|
19
|
|
226
|
|
(33)
|
(33)
|
|
242
|
|
7
|
5
|
Daliresp/Daxas
|
44
|
|
7
|
10
|
|
48
|
|
9
|
9
|
|
53
|
|
10
|
8
|
Tudorza/Eklira
|
37
|
|
3
|
6
|
|
34
|
|
(8)
|
(8)
|
|
37
|
|
9
|
6
|
Duaklir
|
19
|
|
-
|
-
|
|
16
|
|
(16)
|
(15)
|
|
21
|
|
31
|
18
|
Bevespi
|
1
|
|
(67)
|
(50)
|
|
3
|
|
n/m
|
n/m
|
|
4
|
|
33
|
33
|
Others
|
66
|
|
(20)
|
(19)
|
|
66
|
|
-
|
(4)
|
|
67
|
|
2
|
4
|
Total Respiratory
|
1,181
|
|
(2)
|
(1)
|
|
1,099
|
|
(7)
|
(8)
|
|
1,092
|
|
(1)
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
461
|
|
(6)
|
(4)
|
|
595
|
|
29
|
28
|
|
469
|
|
(21)
|
(22)
|
Synagis
|
230
|
|
(24)
|
(24)
|
|
70
|
|
(70)
|
(70)
|
|
153
|
|
n/m
|
n/m
|
Losec/Prilosec
|
68
|
|
15
|
18
|
|
68
|
|
-
|
(3)
|
|
66
|
|
(3)
|
(6)
|
Seroquel XR
|
67
|
|
(43)
|
(42)
|
|
95
|
|
42
|
38
|
|
62
|
|
(35)
|
(36)
|
Movantik/Moventig
|
30
|
|
15
|
15
|
|
32
|
|
7
|
7
|
|
30
|
|
(6)
|
(6)
|
FluMist/Fluenz
|
-
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
|
20
|
|
n/m
|
n/m
|
Others
|
142
|
|
(42)
|
(41)
|
|
213
|
|
50
|
51
|
|
191
|
|
(10)
|
(11)
|
Total Other
|
998
|
|
(24)
|
(22)
|
|
1,073
|
|
8
|
7
|
|
991
|
|
(8)
|
(9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL PRODUCT SALES
|
4,843
|
|
(8)
|
(6)
|
|
4,940
|
|
2
|
1
|
|
4,882
|
|
(1)
|
(3)
|
|
Q1 2016
$m
|
|
Actual
%
|
CER
%
|
|
Q2 2016
$m
|
|
Actual
%
|
CER%
|
|
Q3 2016
$m
|
|
Actual
%
|
CER
%
|
|
Q4 2016
$m
|
|
Actual
%
|
CER
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
51
|
|
183
|
200
|
|
92
|
|
80
|
82
|
|
133
|
|
45
|
44
|
|
147
|
|
11
|
11
|
Iressa
|
135
|
|
5
|
5
|
|
135
|
|
-
|
(2)
|
|
125
|
|
(7)
|
(8)
|
|
118
|
|
(6)
|
(4)
|
Lynparza
|
44
|
|
22
|
22
|
|
54
|
|
23
|
23
|
|
58
|
|
7
|
7
|
|
62
|
|
7
|
9
|
Imfinzi
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faslodex
|
190
|
|
3
|
3
|
|
211
|
|
11
|
9
|
|
207
|
|
(2)
|
(2)
|
|
222
|
|
7
|
9
|
Zoladex
|
178
|
|
(10)
|
(8)
|
|
204
|
|
15
|
8
|
|
199
|
|
(2)
|
(2)
|
|
235
|
|
18
|
11
|
Casodex
|
62
|
|
(2)
|
(6)
|
|
63
|
|
2
|
-
|
|
62
|
|
(2)
|
(5)
|
|
60
|
|
(3)
|
(2)
|
Arimidex
|
57
|
|
(5)
|
(5)
|
|
62
|
|
9
|
7
|
|
56
|
|
(10)
|
(13)
|
|
57
|
|
2
|
5
|
Others
|
21
|
|
(22)
|
(22)
|
|
27
|
|
29
|
12
|
|
27
|
|
-
|
4
|
|
29
|
|
7
|
-
|
Total Oncology
|
738
|
|
3
|
3
|
|
848
|
|
15
|
12
|
|
867
|
|
2
|
2
|
|
930
|
|
7
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CVMD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brilinta
|
181
|
|
4
|
5
|
|
214
|
|
18
|
16
|
|
208
|
|
(3)
|
(2)
|
|
236
|
|
13
|
15
|
Farxiga
|
165
|
|
9
|
10
|
|
211
|
|
28
|
26
|
|
220
|
|
4
|
4
|
|
239
|
|
9
|
9
|
Onglyza
|
211
|
|
10
|
12
|
|
191
|
|
(9)
|
(11)
|
|
169
|
|
(12)
|
(11)
|
|
149
|
|
(12)
|
(11)
|
Bydureon
|
135
|
|
(13)
|
(16)
|
|
156
|
|
16
|
14
|
|
145
|
|
(7)
|
(6)
|
|
142
|
|
(2)
|
(1)
|
Byetta
|
62
|
|
(14)
|
(14)
|
|
76
|
|
23
|
21
|
|
61
|
|
(20)
|
(19)
|
|
55
|
|
(10)
|
(10)
|
Symlin
|
5
|
|
(64)
|
(64)
|
|
10
|
|
n/m
|
n/m
|
|
11
|
|
10
|
10
|
|
14
|
|
27
|
27
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Crestor
|
1,156
|
|
(13)
|
(13)
|
|
926
|
|
(20)
|
(21)
|
|
688
|
|
(26)
|
(26)
|
|
631
|
|
(8)
|
(7)
|
Seloken/Toprol-XL
|
185
|
|
16
|
11
|
|
189
|
|
2
|
-
|
|
185
|
|
(2)
|
(2)
|
|
178
|
|
(4)
|
(2)
|
Atacand
|
71
|
|
(17)
|
(15)
|
|
89
|
|
25
|
22
|
|
74
|
|
(17)
|
(19)
|
|
81
|
|
9
|
14
|
Others
|
121
|
|
(9)
|
(16)
|
|
106
|
|
(12)
|
(11)
|
|
84
|
|
(21)
|
(19)
|
|
86
|
|
2
|
-
|
Total CVMD
|
2,292
|
|
(7)
|
(7)
|
|
2,168
|
|
(5)
|
(7)
|
|
1,845
|
|
(15)
|
(15)
|
|
1,811
|
|
(2)
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
749
|
|
(13)
|
(12)
|
|
803
|
|
7
|
6
|
|
697
|
|
(13)
|
(13)
|
|
740
|
|
6
|
8
|
Pulmicort
|
310
|
|
13
|
14
|
|
239
|
|
(23)
|
(23)
|
|
224
|
|
(6)
|
(6)
|
|
288
|
|
29
|
31
|
Daliresp/Daxas
|
31
|
|
(3)
|
(3)
|
|
40
|
|
29
|
29
|
|
42
|
|
5
|
5
|
|
41
|
|
(2)
|
(2)
|
Tudorza/Eklira
|
39
|
|
(17)
|
(17)
|
|
48
|
|
23
|
21
|
|
47
|
|
(2)
|
-
|
|
36
|
|
(23)
|
(23)
|
Duaklir
|
13
|
|
8
|
8
|
|
17
|
|
31
|
31
|
|
14
|
|
(18)
|
(18)
|
|
19
|
|
36
|
43
|
Bevespi
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
3
|
|
n/m
|
n/m
|
Others
|
65
|
|
-
|
(3)
|
|
79
|
|
22
|
18
|
|
86
|
|
9
|
12
|
|
83
|
|
(3)
|
1
|
Total Respiratory
|
1,207
|
|
(6)
|
(6)
|
|
1,226
|
|
2
|
1
|
|
1,110
|
|
(9)
|
(9)
|
|
1,210
|
|
9
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
463
|
|
(18)
|
(18)
|
|
562
|
|
21
|
20
|
|
516
|
|
(8)
|
(9)
|
|
491
|
|
(5)
|
(4)
|
Synagis
|
244
|
|
(11)
|
(11)
|
|
27
|
|
(89)
|
(89)
|
|
104
|
|
n/m
|
n/m
|
|
302
|
|
n/m
|
n/m
|
Losec/Prilosec
|
75
|
|
(3)
|
(4)
|
|
70
|
|
(7)
|
(9)
|
|
72
|
|
3
|
4
|
|
59
|
|
(18)
|
(17)
|
Seroquel XR
|
202
|
|
(16)
|
(16)
|
|
225
|
|
11
|
11
|
|
190
|
|
(16)
|
(16)
|
|
118
|
|
(38)
|
(37)
|
Movantik/Moventig
|
17
|
|
13
|
13
|
|
23
|
|
35
|
35
|
|
25
|
|
9
|
9
|
|
26
|
|
4
|
4
|
FluMist/Fluenz
|
5
|
|
(97)
|
(97)
|
|
6
|
|
20
|
20
|
|
26
|
|
n/m
|
n/m
|
|
67
|
|
n/m
|
n/m
|
Others
|
322
|
|
(15)
|
(7)
|
|
314
|
|
(2)
|
(4)
|
|
270
|
|
(14)
|
(16)
|
|
246
|
|
(9)
|
(8)
|
Total Other
|
1,328
|
|
(24)
|
(22)
|
|
1,227
|
|
(8)
|
(9)
|
|
1,203
|
|
(2)
|
(3)
|
|
1,309
|
|
9
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL PRODUCT SALES
|
5,565
|
|
(10)
|
(10)
|
|
5,469
|
|
(2)
|
(3)
|
|
5,025
|
|
(8)
|
(8)
|
|
5,260
|
|
5
|
6
|
|
Q1 2015
$m
|
|
Actual
%
|
CER
%
|
|
Q2 2015
$m
|
|
Actual
%
|
CER%
|
|
Q3 2015
$m
|
|
Actual
%
|
CER
%
|
|
Q4 2015
$m
|
|
Actual
%
|
CER
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
18
|
|
n/m
|
n/m
|
Iressa
|
144
|
|
(4)
|
-
|
|
129
|
|
(10)
|
(8)
|
|
141
|
|
9
|
10
|
|
129
|
|
(9)
|
(7)
|
Lynparza
|
9
|
|
n/m
|
n/m
|
|
21
|
|
133
|
133
|
|
28
|
|
33
|
33
|
|
36
|
|
29
|
29
|
Imfinzi
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faslodex
|
161
|
|
(12)
|
(6)
|
|
172
|
|
7
|
8
|
|
186
|
|
8
|
8
|
|
185
|
|
(1)
|
1
|
Zoladex
|
194
|
|
(15)
|
(9)
|
|
215
|
|
11
|
11
|
|
209
|
|
(3)
|
-
|
|
198
|
|
(5)
|
(2)
|
Casodex
|
70
|
|
(5)
|
1
|
|
69
|
|
(1)
|
-
|
|
65
|
|
(6)
|
(4)
|
|
63
|
|
(3)
|
(1)
|
Arimidex
|
62
|
|
(9)
|
(5)
|
|
64
|
|
3
|
7
|
|
64
|
|
-
|
-
|
|
60
|
|
(6)
|
(5)
|
Others
|
34
|
|
(13)
|
(10)
|
|
37
|
|
9
|
9
|
|
35
|
|
(5)
|
-
|
|
27
|
|
(23)
|
(16)
|
Total Oncology
|
674
|
|
(9)
|
(4)
|
|
707
|
|
5
|
6
|
|
728
|
|
3
|
5
|
|
716
|
|
(2)
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CVMD
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brilinta
|
131
|
|
(2)
|
3
|
|
144
|
|
10
|
13
|
|
170
|
|
18
|
19
|
|
174
|
|
2
|
4
|
Farxiga
|
76
|
|
(19)
|
(18)
|
|
129
|
|
70
|
75
|
|
135
|
|
5
|
5
|
|
152
|
|
13
|
14
|
Onglyza
|
183
|
|
(9)
|
(5)
|
|
208
|
|
14
|
15
|
|
203
|
|
(2)
|
(2)
|
|
192
|
|
(5)
|
(5)
|
Bydureon
|
123
|
|
-
|
8
|
|
140
|
|
14
|
11
|
|
162
|
|
16
|
13
|
|
155
|
|
(4)
|
(1)
|
Byetta
|
90
|
|
30
|
35
|
|
82
|
|
(9)
|
(9)
|
|
72
|
|
(12)
|
(12)
|
|
72
|
|
-
|
1
|
Symlin
|
16
|
|
60
|
60
|
|
13
|
|
(19)
|
(19)
|
|
5
|
|
(62)
|
(62)
|
|
14
|
|
n/m
|
n/m
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Crestor
|
1,167
|
|
(16)
|
(13)
|
|
1,310
|
|
12
|
14
|
|
1,218
|
|
(7)
|
(7)
|
|
1,322
|
|
9
|
9
|
Seloken/Toprol-XL
|
194
|
|
11
|
22
|
|
184
|
|
(5)
|
(4)
|
|
172
|
|
(7)
|
(3)
|
|
160
|
|
(7)
|
-
|
Atacand
|
95
|
|
(19)
|
(11)
|
|
99
|
|
4
|
9
|
|
78
|
|
(21)
|
(19)
|
|
86
|
|
10
|
13
|
Others
|
155
|
|
(7)
|
7
|
|
143
|
|
(8)
|
(7)
|
|
132
|
|
(8)
|
(7)
|
|
133
|
|
1
|
4
|
Total CVMD
|
2,230
|
|
(10)
|
(6)
|
|
2,452
|
|
10
|
12
|
|
2,347
|
|
(4)
|
(4)
|
|
2,460
|
|
5
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
845
|
|
(14)
|
(9)
|
|
842
|
|
-
|
2
|
|
848
|
|
1
|
1
|
|
859
|
|
1
|
3
|
Pulmicort
|
286
|
|
6
|
11
|
|
232
|
|
(19)
|
(17)
|
|
222
|
|
(4)
|
(6)
|
|
274
|
|
23
|
26
|
Daliresp/Daxas
|
7
|
|
n/m
|
n/m
|
|
32
|
|
n/m
|
n/m
|
|
33
|
|
3
|
3
|
|
32
|
|
(3)
|
(3)
|
Tudorza/Eklira
|
30
|
|
n/m
|
n/m
|
|
55
|
|
83
|
90
|
|
58
|
|
5
|
5
|
|
47
|
|
(19)
|
(19)
|
Duaklir
|
2
|
|
n/m
|
n/m
|
|
5
|
|
n/m
|
n/m
|
|
8
|
|
60
|
60
|
|
12
|
|
50
|
50
|
Bevespi
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Others
|
73
|
|
(4)
|
12
|
|
59
|
|
(19)
|
(20)
|
|
61
|
|
3
|
3
|
|
65
|
|
7
|
11
|
Total Respiratory
|
1,243
|
|
(7)
|
(2)
|
|
1,225
|
|
(1)
|
1
|
|
1,230
|
|
-
|
-
|
|
1,289
|
|
5
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
644
|
|
(23)
|
(20)
|
|
647
|
|
-
|
3
|
|
641
|
|
(1)
|
(2)
|
|
564
|
|
(12)
|
(10)
|
Synagis
|
204
|
|
(50)
|
(50)
|
|
66
|
|
(68)
|
(68)
|
|
117
|
|
77
|
77
|
|
275
|
|
135
|
135
|
Losec/Prilosec
|
96
|
|
(13)
|
(8)
|
|
85
|
|
(11)
|
(9)
|
|
82
|
|
(4)
|
(5)
|
|
77
|
|
(6)
|
(2)
|
Seroquel XR
|
262
|
|
(15)
|
(13)
|
|
264
|
|
1
|
4
|
|
258
|
|
(2)
|
(2)
|
|
241
|
|
(7)
|
(6)
|
Movantik/Moventig
|
3
|
|
n/m
|
n/m
|
|
1
|
|
(67)
|
(67)
|
|
10
|
|
n/m
|
n/m
|
|
15
|
|
50
|
50
|
FluMist/Fluenz
|
7
|
|
(95)
|
(94)
|
|
14
|
|
n/m
|
n/m
|
|
76
|
|
n/m
|
n/m
|
|
191
|
|
n/m
|
n/m
|
Others
|
385
|
|
12
|
16
|
|
375
|
|
(3)
|
1
|
|
361
|
|
(4)
|
2
|
|
379
|
|
5
|
2
|
Total Other
|
1,601
|
|
(25)
|
(24)
|
|
1,452
|
|
(9)
|
(7)
|
|
1,545
|
|
6
|
8
|
|
1,742
|
|
13
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL PRODUCT SALES
|
5,748
|
|
(14)
|
(10)
|
|
5,836
|
|
2
|
3
|
|
5,850
|
|
-
|
1
|
|
6,207
|
|
6
|
7
|
Announcement of full year and final quarter 2017
results
|
2 February 2018
|
|
Announcement of first quarter 2018 results
|
18 May 2018
|
|
Annual General Meeting
|
18 May 2018
|
|
|
|
|
Future dividends will normally be paid as follows:
|
|
|
First interim
|
Announced with half-year and second-quarter results and paid in
September
|
|
Second interim
|
Announced with full-year and fourth-quarter results and paid in
March
|
|
|
|
|
|
Addresses
for Correspondence
|
|||
Registered Office
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2
0AA
UK
|
Registrar and
Transfer Office
Equiniti
Limited
Aspect
House
Spencer
Road
Lancing
West
Sussex
BN99
6DA
UK
|
Swedish Central Securities Depository
Euroclear
Sweden AB
PO Box
191
SE-101
23 Stockholm
Sweden
|
US Depositary
Citibank Shareholder Services
PO Box
43077
Providence
RI
02940-3077
USA
|
Tel:
+44 (0)20 3749 5000
|
Tel
(Freephone in UK):
0800
389 1580
Tel
(outside UK):+44 (0)121 415 7033
|
Tel:
+46 (0)8 402 9000
|
Tel:
(toll free in the US)
+1
(888) 697 8018
Tel:
(outside the US)
+1
(781) 575 4555
citibank@shareholders-online.com
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|